

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAY 01	New CAS web site launched
NEWS	3	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	7	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	8	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	9	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	10	JUN 29	STN Viewer now available
NEWS	11	JUN 29	STN Express, Version 8.2, now available
NEWS	12	JUL 02	LEMBASE coverage updated
NEWS	13	JUL 02	LMEDLINE coverage updated
NEWS	14	JUL 02	SCISEARCH enhanced with complete author names
NEWS	15	JUL 02	CHEMCATS accession numbers revised
NEWS	16	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	17	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	18	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	20	JUL 30	USGENE now available on STN
NEWS	21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	22	AUG 06	BEILSTEIN updated with new compounds
NEWS	23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	24	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	25	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	27	AUG 27	USPATOLD now available on STN
NEWS	28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:35:14 ON 05 SEP 2007

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:35:28 ON 05 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2007 HIGHEST RN 946048-22-2

DICTIONARY FILE UPDATES: 4 SEP 2007 HIGHEST RN 946048-22-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10083245z.str



```

chain nodes :
10 11 13 15 18 19
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
17
chain bonds :
2-13 3-11 4-10 8-19 9-18 10-15 10-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-13 3-4 3-11 4-5 4-10 5-6 5-7 6-9 7-8 8-9 8-19 9-18
10-15 10-17
isolated ring systems :
containing 1 :
```

G1:C,H,CN,X,Cb

G2:C,H,O,N,CN,X

G3:H,CH3

```


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 13:CLASS 15:CLASS 17:CLASS 18:Atom 19:CLASS
```

L1 STRUCTURE UPLOADED

```

=> d 11
L1 HAS NO ANSWERS
```

L1 STR



G1 C, H, CN, X, Cb

G2 C, H, O, N, CN, X

G3 H, Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

SAMPLE SEARCH INITIATED 09:35:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 649 TO ITERATE

100.0% PROCESSED 649 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 11452 TO 14508

PROJECTED ANSWERS: 1164 TO 2276

L2 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:36:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 13428 TO ITERATE

100.0% PROCESSED 13428 ITERATIONS

1724 ANSWERS

SEARCH TIME: 00.00.01

L3 1724 SEA SSS FUL L1

=> fil capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 09:36:14 ON 05 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2007 VOL 147 ISS 11
FILE LAST UPDATED: 4 Sep 2007 (20070904/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 61 L3

=> s 14 and (py<2003 or ay<2003 or pry<2003)

22888649 PY<2003

4459241 AY<2003

3937862 PRY<2003

L5 38 L4 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d 15 ibib hitstr abs 1-38

L5 ANSWER 1 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:359151 CAPLUS
DOCUMENT NUMBER: 146:380002
TITLE: Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 144pp., Cont.-in-part of U.S. Ser. No. 245,401.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007072881	A1	20070329	US 2006-542920	20061004 <--
CN 1880317	A	20061220	CN 2006-10101322	20030903 <--
US 7161003	B2	20070109	US 2003-654546	20030903 <--
US 2007037824	A1	20070215		
US 2004209878	A1	20041021	US 2004-776988	20040211 <--
US 7119200	B2	20061010		
US 2006128725	A1	20060615	US 2005-245401	20051006 <--
US 7196078	B2	20070327		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117 <--
PRIORITY APPLN. INFO.:			US 2002-408027P	P 20020904 <--
			US 2002-421959P	P 20021029 <--
			US 2003-654546	A2 20030903
			US 2004-776988	A2 20040211
			US 2005-245401	A2 20051006
			CN 2003-824997	A3 20030903


IT 930594-83-5P 930594-85-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors)


RN 930594-83-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-methyl-N-4-piperidinyl-3-(4-pyridinyl)- (CA INDEX NAME)





RN 930594-85-7 CAPLUS

CN 1,3-Propanediamine, N1-[5-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)



GI



AB Title compds. I [R = H, alkyl, alkenyl, etc.; R2 = H, CF3, alkyl, heterocyclyl, etc.; R3 = H, halo, OH, SH, alkyl, etc.; R4 = H, halo or alkyl], and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of cyclin dependent kinases (CDKs). Thus, e.g., II was prepared by amination of III (preparation given) followed by deprotection.


Methods for in vitro kinase assays are described, e.g., II was found to possess an IC50 value of 10 (μ M). Further disclosed are pharmaceutical compns. containing one or more of I, methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns.

L5 ANSWER 2 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2007:359119 CAPLUS
DOCUMENT NUMBER: 146:380001
TITLE: Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Siddiqui, M. Arshad; Reddy, Panduranga Adulla P.; Belanger, David B.; Hamann, Blake; Curran, Patrick J.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 60pp., Cont.-in-part of U.S. Ser. No. 244,776.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007072882	A1	20070329	US 2006-543182	20061004 <--
US 2004102451	A1	20040527	US 2003-654157	20030903 <--
US 7078525	B2	20060718		
US 2006040958	A1	20060223	US 2005-244776	20051006 <--
US 7196092	B2	20070327		
PRIORITY APPLN. INFO.:			US 2002-408030P	P 20020904 <--
			US 2003-654157	A2 20030903
			US 2005-244776	A2 20051006

OTHER SOURCE(S): MARPAT 146:380001
IT 930299-25-5P 930299-26-6P 930299-44-8P
930299-45-9P 930300-17-7P 930300-18-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin dependent kinase inhibitors)
RN 930299-25-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-methyl-5-isothiazolyl)-3-(1-methyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 930299-26-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-methyl-N-(3-methyl-5-isothiazolyl)-3-(4-pyridinyl)- (CA INDEX NAME)



RN 930299-44-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-methyl-5-isothiazolyl)-3-(1H-pyrazol-4-yl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 930299-45-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[3-(4-piperidinyl)-5-isothiazolyl]-3-(1H-pyrazol-4-yl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 930300-17-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-methyl-5-isothiazolyl)-3-(1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 930300-18-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[3-(4-piperidinyl)-5-isothiazolyl]-3-(1H-pyrazol-4-yl)- (CA INDEX NAME)



IT 930299-96-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolopyrimidines as cyclin dependent kinase inhibitors)
 RN 930299-96-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(3-methyl-5-isothiazolyl)-3-
 (1-methyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted heteroaryl; R2 = alkyl, alkynyl, CF3, aryl, etc.; R3 = H, halo, alkyl, heteroaryl, etc.; R4 = H, halo or alkyl], and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of cyclin dependent kinases (CDKs). Thus, e.g., II was prepared by substitution of III (preparation given) with 3-aminoazetidine. In in vitro kinase activity assays, select compds. of the invention demonstrated IC50 values ranging from 0.05 - 49 (μ M). Further disclosed are

pharmaceutical compns. containing one or more of I, methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns.

L5 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:579598 CAPLUS
DOCUMENT NUMBER: 145:62916
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 1068 pp., Cont.-in-part of U.S. Ser. No. 776,988.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006128725	A1	20060615	US 2005-245401	20051006 <--
US 7196078	B2	20070327		
CN 1880317	A	20061220	CN 2006-10101322	20030903 <--
US 7161003	B2	20070109	US 2003-654546	20030903 <--
US 2007037824	A1	20070215		
US 2004209878	A1	20041021	US 2004-776988	20040211 <--
US 7119200	B2	20061010		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117 <--
US 2007072881	A1	20070329	US 2006-542920	20061004 <--
WO 2007044449	A2	20070419	WO 2006-US38939	20061004
WO 2007044449	A3	20070524		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:
US 2002-408027P P 20020904 <--
US 2002-421959P P 20021029 <--
US 2003-654546 A2 20030903
US 2004-776988 A2 20040211
CN 2003-824997 A3 20030903
US 2005-245401 A2 20051006

OTHER SOURCE(S): MARPAT 145:62916

IT 779353-05-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)


RN 779353-05-8 CAPLUS

CN Cyclohexanemethanol, 2-[[3-cyclopropyl-7-[[1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-, (1R,2S)-(9CI) (CA INDEX NAME)




Absolute stereochemistry.



IT 779353-66-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
 RN 779353-66-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-cyclopropyl-N-[(1-oxido-3-
 pyridinyl)methyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:167936 CAPLUS
DOCUMENT NUMBER: 144:254145
TITLE: Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 653,776.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006041131	A1	20060223	US 2005-244772	20051006 <--
US 7205308	B2	20070417		
US 2004106624	A1	20040603	US 2003-653776	20030903 <--
US 7067661	B2	20060627		
US 2006178371	A1	20060810	US 2006-395676	20060331 <--
US 2007072880	A1	20070329	US 2006-542833	20061004 <--
WO 2007044420	A1	20070419	WO 2006-US38838	20061004

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:
US 2002-408029P P 20020904 <--
US 2003-653776 A2 20030903
US 2005-244772 A2 20051006

OTHER SOURCE(S): MARPAT 144:254145


IT 877173-69-8P 877173-71-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors for treatment and prevention of diseases)


RN 877173-69-8 CAPLUS

CN 1,3-Benzenediamine, N,N-dimethyl-N'-[3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)





RN 877173-71-2 CAPLUS

CN Phenol, 4-[[3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)



GI



AB The title compds. I [R = aryl optionally substituted with one or more heteroaryl; R2 = alkyl, cycloalkyl, CF₃, etc.; R3 = H, halo, alkyl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases, were prepared. Thus, reacting II (preparation given) with 4-methylsulfonylaniline hydrochloride in the presence of iPr₂NEt afforded 23% III. The compds. I were tested in in vitro cyclin E/CDK2 kinase assay (biol. data given for representative compds. I). The invention also provides pharmaceutical compns. containing one or more compds. I, methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns.

L5 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:878151 CAPLUS
DOCUMENT NUMBER: 141:366243
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamilus; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacoepia, Inc.
SOURCE: U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209878	A1	20041021	US 2004-776988	20040211 <--
US 7119200	B2	20061010		
CN 1880317	A	20061220	CN 2006-10101322	20030903 <--
US 7161003	B2	20070109	US 2003-654546	20030903 <--
US 2007037824	A1	20070215		
AU 2005212409	A1	20050825	AU 2005-212409	20050208
CA 2555345	A1	20050825	CA 2005-2555345	20050208
WO 2005077954	A2	20050825	WO 2005-US3859	20050208
WO 2005077954	A3	20051013		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1720882	A2	20061115	EP 2005-722809	20050208
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
CN 1946725	A	20070411	CN 2005-80012293	20050208
BR 2005007644	A	20070417	BR 2005-7644	20050208
JP 2007522220	T	20070809	JP 2006-553181	20050208
US 2006128725	A1	20060615	US 2005-245401	20051006 <--
US 7196078	B2	20070327		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117 <--
US 2007054906	A1	20070308	US 2006-396001	20060331 <--
US 2007054925	A1	20070308	US 2006-396079	20060331 <--
IN 2006CN02909	A	20070608	IN 2006-CN2909	20060808
MX 2006PA09245	A	20061110	MX 2006-PA9245	20060811
NO 2006004046	A	20061110	NO 2006-4046	20060908

US 2007072881	A1	20070329	US 2006-542920	20061004 <--
PRIORITY APPLN. INFO.:			US 2002-408027P	P 20020904 <--
			US 2002-421959P	P 20021029 <--
			US 2003-654546	A2 20030903
			CN 2003-824997	A3 20030903
			US 2004-776988	A 20040211
			WO 2005-US3859	W 20050208
			US 2005-245401	A2 20051006


OTHER SOURCE(S): MARPAT 141:366243

IT 779353-05-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 779353-05-8 CAPLUS

CN Cyclohexanemethanol, 2-[[3-cyclopropyl-7-[[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-, (1R,2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 779353-66-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 779353-66-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-cyclopropyl-N-[(1-oxido-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a

Part

I of I-III series.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:220335 CAPLUS
DOCUMENT NUMBER: 140:270872
TITLE: Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.; Pharmacopeia Drug Discovery, Inc.
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004022560	A1	20040318	WO 2003-US27502	20030903 <--
WO 2004022560	A9	20050707		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497450	A1	20040318	CA 2003-2497450	20030903 <--
AU 2003268385	A1	20040329	AU 2003-268385	20030903 <--
US 2004116442	A1	20040617	US 2003-653868	20030903 <--
US 7074924	B2	20060711		
EP 1534710	A1	20050601	EP 2003-749347	20030903 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1701074	A	20051123	CN 2003-824779	20030903 <--
JP 2006502161	T	20060119	JP 2004-534459	20030903 <--
NZ 539164	A	20060428	NZ 2003-539164	20030903 <--
ZA 2005001852	A	20050908	ZA 2005-1852	20050303 <--
MX 2005PA02570	A	20050908	MX 2005-PA2570	20050304 <--
US 2006173016	A1	20060803	US 2006-395824	20060331 <--
PRIORITY APPLN. INFO.:			US 2002-407999P	P 20020904 <--
			US 2003-653868	A3 20030903
			WO 2003-US27502	W 20030903

OTHER SOURCE(S): MARPAT 140:270872


IT 673475-13-3P 673475-26-8P 673475-27-9P
673475-30-4P 673475-31-5P 673475-34-8P
673475-35-9P 673475-36-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents)


RN 673475-13-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(5-chloro-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl)- (9CI) (CA INDEX NAME)




RN 673475-26-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(cyclopentylamino)-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673475-27-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(cyclohexylamino)-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673475-30-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 673475-31-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 673475-34-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[[1-(hydroxymethyl)cyclopentyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI)
(CA INDEX NAME)



RN 673475-35-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[(1R,2S)-2-(hydroxymethyl)cyclohexyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 673475-36-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[(1R,2R)-2-(hydroxymethyl)cyclohexyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



AB The title compds. [I; Q = SO₂, CO; R = each (un)substituted aryl or heteroaryl; R₂ = cyano, NR₅R₆, CO₂R₆, CONR₅R₆, OR₆, SR₆, SO₂R₇, SO₂NR₅R₆, -N(R₅)SO₂R₇, N(R₅)COR₇, N(R₅)CONR₅R₆, alkynyl, heteroaryl, CF₃, heterocyclyl, alkynylalkyl, cycloalkyl, (un)substituted alkyl; R₃ = H, halogen, NR₅R₆, CONR₅R₆, each (un)substituted alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, etc.; R₄ = H, halo, alkyl; R₅ = H, alkyl; R₆ = H, each (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or R₅ and R₆ in the moiety -NR₅R₆, may be joined together to form an (un)substituted cycloalkyl or heterocyclyl] or pharmaceutically acceptable salts or solvates thereof are prepared. In its many embodiments, the present invention also provides methods of preparing such compds., pharmaceutical compns. containing one or more such compds. I, methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with cyclin dependent kinase using such compds. I or pharmaceutical compns. The disease associated with cyclin dependent kinase is selected from the group consisting of; (1) cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; (2) leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; (3) acute and chronic myelogenous leukemia,

myelodysplastic syndrome and promyelocytic leukemia; (4) fibrosarcoma and rhabdomyosarcoma; (5) astrocytoma, neuroblastoma, glioma and schwannomas; and (6) melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:913167 CAPLUS
DOCUMENT NUMBER: 139:381505
TITLE: Preparation of pyrazolopyrimidines for preventing or
treating herpes virus infection
INVENTOR(S): Gudmundsson, Kristjan S.; Johns, Brian A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095455	A2	20031120	WO 2003-US13395	20030430 <--
WO 2003095455	A3	20031224		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003228770	A1	20031111	AU 2003-228770	20030430 <--
EP 1504004	A2	20050209	EP 2003-726540	20030430 <--
EP 1504004	B1	20070627		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005529919	T	20051006	JP 2004-503469	20030430 <--
AT 365740	T	20070715	AT 2003-726540	20030430 <--
US 2005203106	A1	20050915	US 2004-512916	20041029 <--
PRIORITY APPLN. INFO.:			US 2002-379421P	P 20020510 <--
			WO 2003-US13395	W 20030430

OTHER SOURCE(S): MARPAT 139:381505


IT 625095-79-6P 625095-80-9P 625095-81-0P
625095-82-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazolopyrimidines for preventing or treating herpes virus
infection)


RN 625095-79-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-
pyridinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 625095-80-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 625095-81-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 625095-82-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




IT 625095-87-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrazolopyrimidines for preventing or treating herpes virus infection)

RN 625095-87-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



GI




AB The title compds. [I; p = 1-3; R1 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R2 = aryl, 5-6 membered heterocyclyl or heteroaryl, aryloxy, etc.; R3, R4 = H, halo, alkyl, aryl, etc.; ring A = aryl, 5-10 membered heterocyclyl or heteroaryl; q = 0-5; R5 = halo, alkyl, cycloalkyl, aryl, etc.], useful for the prophylaxis or treatment of a herpes viral infection in an animal, were prepared Thus, coupling 3-bromo-2-phenyl-7-(pyrrolidin-1-

yl)pyrazolo[1,5-a]pyrimidine with 2-fluoropyridin-4-ylboronic acid (preps. given) in the presence of $\text{PdCl}_2(\text{PPh}_3)_2$, Na_2CO_3 and a few drops of H_2O in DMF afforded 32% II which showed IC_{50} of 28 μM against HSV-1. The pharmaceutical compns. containing the compds. I are claimed.


L5 ANSWER 8 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:875291 CAPLUS
DOCUMENT NUMBER: 139:350751
TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives
as NAD(P)H oxidase inhibitors
INVENTOR(S): Seno, Kaoru; Nishi, Koichi; Matsuo, Yoshiyuki;
Fujishita, Toshio
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 240 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091256	A1	20031106	WO 2003-JP5024	20030418 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483306	A1	20031106	CA 2003-2483306	20030418 <--
AU 2003227437	A1	20031110	AU 2003-227437	20030418 <--
EP 1505068	A1	20050209	EP 2003-717663	20030418 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009475	A	20050301	BR 2003-9475	20030418 <--
CN 1662537	A	20050831	CN 2003-814483	20030418 <--
MX 2004PA10441	A	20050214	MX 2004-PA10441	20041022 <--
US 2006089362	A1	20060427	US 2005-511840	20050923 <--
PRIORITY APPLN. INFO.:			JP 2002-121519	A 20020423 <--
			WO 2003-JP5024	W 20030418
OTHER SOURCE(S):	MARPAT 139:350751			
IT 619305-80-5 619306-08-0 619306-32-0 619306-36-4				
RL: PAC (Pharmacological activity); BIOL (Biological study)				
(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)				
RN 619305-80-5 CAPLUS				
CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(methylamino)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)				




RN 619306-08-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(cyclopropylamino)-N-[3-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 619306-32-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(cyclopentylamino)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 619306-36-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(dimethylamino)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



IT 619304-52-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)
 RN 619304-52-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-[(4-fluorophenyl)amino]-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



GI



I

AB Title compds. I (R1, R2, R3, R4, R5 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, , aryl, heteroaryl, etc.) and their pharmaceutically acceptable salts, useful in the prevention of or treatments for diseases relating to NAD(P)H, are prepared Thus, N-2-cyclohexylphenyl 3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amide was prepared in several steps from Et 7-chloropyrazolo[1,5-a]pyrimidine-5-carboxylate.

REFERENCE COUNT: 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:716091 CAPLUS
 DOCUMENT NUMBER: 137:232665
 TITLE: A process for the preparation of a homochiral corticotropin releasing factor receptor ligand
 INVENTOR(S): Gilligan, Paul J.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072101	A1	20020919	WO 2002-US6834	20020306 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002240578	A1	20020924	AU 2002-240578	20020306 <--
PRIORITY APPLN. INFO.: US 2001-275331P P 20010313 <-- WO 2002-US6834 W 20020306 <--				

OTHER SOURCE(S): CASREACT 137:232665

IT 457911-55-6P, (-)-7-((R)-Butan-2-ylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CRF antagonist; process for preparation of a homochiral corticotropin releasing factor receptor ligand)


RN 457911-55-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



AB A process for the preparation of corticotropin releasing factor receptor I was disclosed. 2-Methyl-4-methoxybenzyl bromide (prepn given) was converted to the nitrile (DMF/EtOHaq, NaCN) and acetylated (EtOAc, Na^o, reflux) and reacted with hydrazine to give an intermediate pyrazole. This was reacted with Et acetoacetate (HOAc, reflux) to form 7-hydroxy-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine (II). II was treated with POCl₃ (PhMe, DIEA) and the chloride displaced with (R)-2-butylamine to afford I. I is used in treating anxiety, depression, and other psychiatric, neurol. disorders as well as treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:184863 CAPLUS

DOCUMENT NUMBER: 136:221516

TITLE: Hair growth stimulants containing CRF1 receptor antagonists

INVENTOR(S): Ikeda, Akiko; Okuyama, Shigeru; Shibasaki, Tamotsu; Kawana, Seiji; Kaneko, Katsumi

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019975	A1	20020314	WO 2001-JP7537	20010831 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001084417	A5	20020322	AU 2001-84417	20010831 <--
PRIORITY APPLN. INFO.:			JP 2000-269291	A 20000905 <--
			WO 2001-JP7537	W 20010831 <--


OTHER SOURCE(S): MARPAT 136:221516

IT 202579-74-6

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(hair growth stimulants containing CRF1 receptor antagonists)

RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



AB Disclosed are hair growth stimulants containing a corticotropin release factor (CRF) 1 receptor antagonist as the active ingredient. A CRF1 receptor antagonist 2-[N-(2-methylthio-4-isopropylphenyl)-N-ethylamino]-4-[4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridine-1-yl]-6-methylpyrimidine showed keratinocyte cell proliferation promoting effect in cultured human epidermal keratinocyte cells.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:813420 CAPLUS
 DOCUMENT NUMBER: 135:344507
 TITLE: Preparation of azolotriazines and -pyrimidines as
 corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis,
 Argyrios Georgios
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
 SOURCE: U.S., 57 pp., Cont.-in-part of U.S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6313124	B1	20011106	US 1998-14734	19980128 <--
CA 2532925	A1	19980129	CA 1997-2532925	19970723 <--
US 6124289	A	20000926	US 1997-899242	19970723 <--
ZA 9706603	A	19990125	ZA 1997-6603	19970724 <--
US 6136809	A	20001024	US 1998-14999	19980128 <--
LT 4680	B	20000725	LT 1999-8	19990125 <--
CA 2314613	A1	19990805	CA 1999-2314613	19990128 <--
WO 9938868	A1	19990805	WO 1999-US1824	19990128 <--
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9924787	A	19990816	AU 1999-24787	19990128 <--
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128 <--
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128 <--
JP 2002501922	T	20020122	JP 2000-529335	19990128 <--
NZ 505079	A	20030829	NZ 1999-505079	19990128 <--
EP 1344779	A1	20030917	EP 2003-75887	19990128 <--
EP 1344779	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 264860	T	20040515	AT 1999-904382	19990128 <--
PT 1049699	T	20040831	PT 1999-904382	19990128 <--
CN 1542010	A	20041103	CN 2003-10122546	19990128 <--
ES 2218991	T3	20041116	ES 1999-904382	19990128 <--
SG 111076	A1	20050530	SG 2002-200204556	19990128 <--
AT 301657	T	20050815	AT 2003-75887	19990128 <--
PT 1344779	T	20051031	PT 2003-75887	19990128 <--
ES 2247478	T3	20060301	ES 2003-75887	19990128 <--
TW 520372	B	20030211	TW 1999-88102636	19990223 <--
MX 2000PA06495	A	20011011	MX 2000-PA6495	20000629 <--
US 2003008885	A1	20030109	US 2001-930782	20010816 <--
US 7094782	B1	20060822	US 2003-703235	20031107 <--
HK 1060348	A1	20051021	HK 2004-101985	20040317 <--
JP 2005097257	A	20050414	JP 2004-216483	20040723 <--
US 2006252756	A1	20061109	US 2006-477680	20060629 <--
PRIORITY APPLN. INFO.:			US 1996-23290P	P 19960724 <--
			US 1997-899242	A2 19970723 <--

US 1996-686047	A 19960724 <--
CA 1997-2259583	A3 19970723 <--
JP 1998-507233	A3 19970723 <--
US 1998-14734	A 19980128 <--
US 1998-15001	A 19980128 <--
US 1998-15002	A 19980128 <--
EP 1999-904382	A3 19990128 <--
WO 1999-US1824	W 19990128 <--
US 2001-930782	B1 20010816 <--
US 2003-703235	A1 20031107


OTHER SOURCE(S): MARPAT 135:344507

IT 202579-57-5P 202579-60-0P 202579-62-2P
 202579-63-3P 202579-64-4P 202579-65-5P
 202579-69-9P 202579-73-5P 202579-74-6P
 202579-75-7P 202579-77-9P 202579-78-0P
 202579-80-4P 202579-81-5P 202579-82-6P
 202579-84-8P 202579-87-1P 202579-91-7P
 202579-92-8P 202579-94-0P 202579-95-1P
 202580-25-4P 202580-26-5P 202580-28-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-65-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-69-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-75-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-77-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 202579-78-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 202579-80-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-81-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-82-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-87-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-91-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[(1S)-

(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethoxypropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, alkyl, alkenyl, etc.; R₁ = H, alkyl, alkenyl, etc.; R₂ = H, alkyl, alkenyl, etc.; R₃ = H, SH, OH, etc.; R₁₄ = C₁-10 alkyl, C₃-10 alkenyl, C₃-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists (no data) which are useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POC13 and N,N-dimethylaniline, followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxy-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R₁ = Me; R₃ = NHCH(CH₂OMe)₂; Ar = 2,4-C₁₂H₃].

REFERENCE COUNT: 103 THERE ARE 103 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 12 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:796238 CAPLUS
DOCUMENT NUMBER: 135:339292
TITLE: Combinations of corticotropin releasing factor
antagonists and growth hormone secretagogues
INVENTOR(S): Fossa, Anthony A.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 58 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1149583	A2	20011031	EP 2001-303033	20010330 <--
EP 1149583	A3	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2001001456	A	20011204	BR 2001-1456	20010411 <--
MX 2001PA03855	A	20020604	MX 2001-PA3855	20010411 <--
CA 2344089	A1	20011013	CA 2001-2344089	20010412 <--
US 2001041673	A1	20011115	US 2001-834477	20010413 <--
PRIORITY APPLN. INFO.:			US 2000-196698P	P 20000413 <--


OTHER SOURCE(S): MARPAT 135:339292

IT 202579-62-2 202579-64-4 203924-40-7
203924-41-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of corticotropin releasing factor antagonists and growth hormone secretagogues)


RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 203924-40-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 203924-41-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-5-methyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



AB This invention is directed to pharmaceutical compns. comprising corticotropin releasing factor antagonist and growth hormone or growth hormone secretagogues, prodrugs thereof, or pharmaceutically acceptable salts of said compds. or said prodrugs (Markush structures given). The invention is also directed to the use of such compns. in the treatment or prevention of osteoporosis and heart-related diseases (including congestive heart failure) in mammals, particularly humans (no data).

L5 ANSWER 13 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:435078 CAPLUS

DOCUMENT NUMBER: 135:61346

TITLE: Preparation of fused heterotricyclic compounds as antagonists against corticotropin-releasing factor receptor

INVENTOR(S): Hibi, Shigeki; Hoshino, Yoriyisa; Yoshiuchi, Tatsuya; Shin, Kogyoku; Kikuchi, Kouichi; Soejima, Motohiro; Tabata, Mutsuko; Takahashi, Yoshinori; Shibata, Hisashi; Hida, Takayuki; Hirakawa, Tetsuya; Ino, Mitsuhiro

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan; et al.

SOURCE: PCT Int. Appl., 255 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042247	A1	20010614	WO 2000-JP8811	20001213 <--
W: AU, BR, CA, CN, HU, IL, KR, MX, NO, NZ, RU, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
JP 2001233876	A	20010828	JP 2000-375811	20001211 <--
CA 2394120	A1	20010614	CA 2000-2394120	20001213 <--
AU 2001020235	A5	20010618	AU 2001-20235	20001213 <--
AU 773258	B2	20040520		
EP 1238979	A1	20020911	EP 2000-983479	20001213 <--
EP 1238979	B1	20050302		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1408040	A1	20040414	EP 2003-29058	20001213 <--
EP 1408040	B1	20050727		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
NZ 519241	A	20041224	NZ 2000-519241	20001213 <--
AT 290006	T	20050315	AT 2000-983479	20001213 <--
ES 2234704	T3	20050701	ES 2000-983479	20001213 <--
PT 1238979	T	20050729	PT 2000-983479	20001213 <--
AT 300546	T	20050815	AT 2003-29058	20001213 <--
US 2003078277	A1	20030424	US 2002-148836	20020605 <--
US 6951865	B2	20051004		
US 2005004147	A1	20050106	US 2004-903059	20040802 <--
US 6995163	B2	20060207		
US 2005004159	A1	20050106	US 2004-903387	20040802 <--
US 6927221	B2	20050809		

PRIORITY APPLN. INFO.: JP 1999-352553 A 19991213 <--
EP 2000-983479 A3 20001213 <--
WO 2000-JP8811 W 20001213 <--
US 2002-148836 A3 20020605 <--

OTHER SOURCE(S): MARPAT 135:61346


IT 344291-77-6P 344293-47-6P 344294-07-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of fused heterotricyclic compds. as antagonists against corticotropin-releasing factor receptor for preventives or remedies for CRF and/or CRF receptor-related diseases)


RN 344291-77-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[(1-ethylpropyl)amino]-2,5-dimethyl-3-(2,4,6-trimethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 344293-47-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-acetic acid, 7-[(1-ethylpropyl)amino]-2,5-dimethyl-3-(2,4,6-trimethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 344294-07-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-acetic acid, 7-[(1-ethylpropyl)amino]-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



GI



AB Compds. such as pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine, dipyrazolo[1,5-a:4,3-e]pyrimidine, pyrrolo[3,2-c]quinoline, and pyrrolo[3,2-c][1,7]naphthyridine derivs. represented by general formula [I; A, B, D = N, O, S, (CR₁R₂)_m, CO, CS, (un)substituted NH, SO, SO₂ (wherein m = 0-4; R₁, R₂ = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-8 cycloalkyl, etc.); E, G = N, O, S, (CR₆R₇)_p, CO, CS, (un)substituted NH, SO, SO₂ (wherein R₆, R₇ = H, C1-6 alkyl, optionally C1-4 alkyl-substituted C3-5 cycloalkyl, optionally substituted aryl, or heteroaryl, etc.; p = 0, 1, 2); K, L = C, N; the ring formed by K, E, G, J, and L represents an (un)saturated 5- or 6-membered ring; M = M = H, halo, cyano, (un)substituted C1-6 alkyl, (un)substituted NH, OR₁₃, S(O)_qR₁₄, (un)substituted C2-10 alkenyl or alkynyl, (un)substituted C1-6 alkoxy, C1-6 alkylthio, aryl, or heteroaryl (wherein R₁₃ = H, optionally substituted C1-6 alkyl, C1-4 alkylacyl, optionally substituted aryl-C1-4 alkyl or heteroaryl-C1-4 alkyl, or aryl-heteroaryl; R₁₄ = C1-6 alkyl optionally substituted aryl-C1-4 alkyl, aryl, heteroaryl-C1-4 alkyl, or heteroaryl; q = 0, 1, 2); the solid line accompanied by a dotted line represents a single or a double bond] or pharmacol. acceptable salts thereof or their hydrates, which are also adenylate cyclase inhibitors, are prepared These compds. are useful for the prevention and/treatment of diseases related to corticotropin-releasing factor (CRF) and/or corticotropin-releasing factor receptor. The above diseases include depression, mania, child abuse due to depression, depression after child birth, anxiety, general anxiety, panic disorders, phobia, obsessive-compulsive disorders, post-traumatic-stress disorder, autism, emotional disorders, emotional disturbance, bipolar disorder, , schizophrenia, peptic ulcer, irritable bowel syndrome, ulcerative colitis, Crohn's disease, diarrhea, constipation, intestinal functional abnormality accompanied by stress, neurol. vomiting, Alzheimer's disease, neurodegenerative disease, multiple infarction dementia, and senile dementia, neurol. appetite depression, eating disorders, obesity, diabetes, alc. dependence, drug preference, alc. or drug withdrawal symptom. They also include insomnia, migraine headache, stress headache, muscular stress headache, ischemic nerve disorders, excitatory toxin nerve disorders, stroke, progressive supranuclear paralysis, amyotrophic lateral sclerosis, multiple sclerosis, muscle spasm, chronic fatigue syndrome, neurol. social growth-retardation, epilepsy, head injury, spinal injury, writer's cramp, torticollis spastica, cervicobrachial syndrome, Meniere's syndrome, vegetative dystonia, hair loss, neuropathy, hypertension, cardiovascular disorders, tachycardia, congestive heart attack, hyperpnea syndrome, bronchial asthma, apnea syndrome, sudden infant death syndrome, inflammatory disorders, pain, allergy, impotence, menopausal syndrome, fertilization disorder, sterility, cancer, immune function disorders during HIV infection or caused by stress, hemorrhagic stress, Cushing's disease, thyroid gland function abnormality, meningitis, acromegaly, incontinence, and osteoporosis, etc. Thus, a solution of 7-chloro-6-(2-chloroethyl)-3-mesityl-2,5-dimethylpyrazolo[1,5-a]pyrimidine

and 3-aminopentane in Me Et ketone was refluxed for 1 h to give, after treatment with HCl in Et₂O, 8-(1-ethylpropyl)-3-mesityl-2,5-dimethyl-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine hydrochloride (II). II showed IC₅₀ of 100 nM for inhibiting the binding of [125I]sauvagine to human CRF receptor expressed in HEK 293 cells and showed IC₅₀ of 900 nM against adenylic acid cyclase.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:338070 CAPLUS
DOCUMENT NUMBER: 134:336224
TITLE: Use of corticotropin releasing factor (CRF)
antagonists for treating syndrome X
INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097709	A2	20010509	EP 2000-309441	20001026 <--
EP 1097709	A3	20051221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AU 776724	B2	20040916	AU 2000-66695	20001024 <--
ZA 2000006008	A	20020426	ZA 2000-6008	20001026 <--
US 6589947	B1	20030708	US 2000-696822	20001026 <--
CA 2325069	A1	20010429	CA 2000-2325069	20001027 <--
HU 200004194	A2	20011228	HU 2000-4194	20001027 <--
NZ 507825	A	20041126	NZ 2000-507825	20001027 <--
US 2007117805	A1	20070524	US 2006-580996	20061013 <--
PRIORITY APPLN. INFO.:			US 1999-162340P	P 19991029 <--
			US 2000-559384	A3 20000427 <--
			US 2002-80174	A1 20020219 <--
			US 2003-721318	A1 20031125

OTHER SOURCE(S): MARPAT 134:336224


IT 202579-62-2 202579-64-4 203924-40-7
203924-41-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)


RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 203924-40-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 203924-41-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-5-methyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



AB Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

L5 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:247337 CAPLUS

DOCUMENT NUMBER: 134:280853

TITLE: Preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists

INVENTOR(S): Darrow, James W.; De Lombaert, Stephane; Blum, Charles; Tran, Jennifer; Giangordano, Mark; Griffith, David Andrew; Carpino, Philip Albert

PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023388	A2	20010405	WO 2000-US26885	20000929 <--
WO 2001023388	A3	20011018		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2379633	A1	20010405	CA 2000-2379633	20000929 <--
CA 2379633	C	20060620		
EP 1218381	A2	20020703	EP 2000-967132	20000929 <--
EP 1218381	B1	20061206		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
US 6476038	B1	20021105	US 2000-676972	20000929 <--
HU 200203131	A2	20030128	HU 2002-3131	20000929 <--
JP 2003510326	T	20030318	JP 2001-526540	20000929 <--
AT 347553	T	20061215	AT 2000-967132	20000929 <--
ES 2277855	T3	20070801	ES 2000-967132	20000929 <--
BG 106507	A	20021229	BG 2002-106507	20020311 <--
NO 2002001357	A	20020523	NO 2002-1357	20020319 <--
ZA 2002002517	A	20030328	ZA 2002-2517	20020328 <--
JP 2007077144	A	20070329	JP 2006-241067	20060906 <--
PRIORITY APPLN. INFO.:			US 1999-156868P	P 19990930 <--
			JP 2001-526540	A3 20000929 <--
			WO 2000-US26885	W 20000929 <--

OTHER SOURCE(S): MARPAT 134:280853


IT 332225-19-1P 332225-26-0P 332225-31-7P
332225-45-3P 332225-51-1P 332225-68-0P
332225-74-8P 332225-80-6P 332225-86-2P
332225-92-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists)


RN 332225-19-1 CAPLUS

CN 1,2-Ethanediamine, N-[3-(4-chloro-2,6-dimethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)




RN 332225-26-0 CAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,3-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 332225-31-7 CAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 332225-45-3 CAPLUS
 CN 1,2-Ethanediamine, N-cyclohexyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332225-51-1 CAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332225-68-0 CAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332225-74-8 CAPLUS

CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-ethynylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 332225-80-6 CAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-ethynylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332225-86-2 CAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-[2,6-dichloro-4-(1-cyclopenten-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)


Cc1c(Cl)ccc(cc1C2=CN(C(=N2)C3=C(C)N(CCN3C4CCCC4)C5CCCC5)C)C

Page 64


PAGE 1-A




PAGE 2-A




IT 332179-38-1P 332227-43-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and
pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists)
RN 332179-38-1 CAPLUS
CN 1,2-Ethanediamine, N-[3-(4-chloro-2,6-dimethylphenyl)-2,5-
dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 332227-43-7 CAPLUS
 CN Carbamic acid, cyclopentyl[2-[[3-(2,3-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; N, CR14; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; A = (un)substituted (CH2)_m (wherein m = 1-3); B = (un)substituted (CH2)_n (n = 0-3); R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl; R5, R6 = H, alkyl, cycloalkyl, etc.] that are selective modulators of NPY1 receptors, and are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension, were prepared E.g., a multi-step synthesis of the pyrazolo[1,5-a]pyrimidine II was

described. The NPY1 receptor binding affinity for the compds. I, expressed as a K_i , ranges from 0.1 nM to 10 μ M. The compds. I are also useful as probes for the localization of NPY1 receptors and as stds. in assays for NPY1 receptor binding. Compds. I were also tested for CRF1 receptor binding affinity.

L5 ANSWER 16 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:247336 CAPLUS
DOCUMENT NUMBER: 134:280866
TITLE: Preparation of certain alkylene diamine-substituted
pyrazolo[1,5-a]-1,5-pyrimidines and
pyrazolo[1,5-a]-1,3,5-triazines as selective
modulators of NPY1 receptors
INVENTOR(S): Darrow, James W.; De Lombaert, Stephane; Blum,
Charles; Tran, Jennifer; Giangordano, Mark; Griffith,
David Andrew; Carpino, Philip Albert
PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.; De Lombaert,
Stephane
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2001023387	A2	20010405	WO 2000-US26887	20000929 <--
WO 2001023387	A3	20020124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2379585	A1	20010405	CA 2000-2379585	20000929 <--
CA 2379585	C	20060620		
US 6372743	B1	20020416	US 2000-676970	20000929 <--
EP 1218379	A2	20020703	EP 2000-967134	20000929 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
HU 200202678	A2	20021228	HU 2002-2678	20000929 <--
JP 2003510325	T	20030318	JP 2001-526539	20000929 <--
US 2003069246	A1	20030410	US 2002-83245	20020225 <--
BG 106506	A	20021229	BG 2002-106506	20020311 <--
NO 2002001356	A	20020523	NO 2002-1356	20020319 <--
ZA 2002002519	A	20031128	ZA 2002-2519	20020328 <--
PRIORITY APPLN. INFO.:			US 1999-156869P	P 19990930 <--
			US 2000-676970	A1 20000929 <--
			WO 2000-US26887	W 20000929 <--

OTHER SOURCE(S): MARPAT 134:280866

IT 332178-43-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)

RN 332178-43-5 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-,

hydrochloride (9CI) (CA INDEX NAME)




IT	332178-32-2P	332178-33-3P	332178-34-4P
	332178-35-5P	332178-37-7P	332178-38-8P
	332178-39-9P	332178-40-2P	332178-41-3P
	332178-42-4P	332178-44-6P	332178-45-7P
	332178-46-8P	332178-47-9P	332178-48-0P
	332178-49-1P	332178-50-4P	332178-51-5P
	332178-52-6P	332178-53-7P	332178-54-8P
	332178-55-9P	332178-56-0P	332178-57-1P
	332178-59-3P	332178-60-6P	332178-61-7P
	332178-62-8P	332178-63-9P	332178-64-0P
	332178-65-1P	332178-66-2P	332178-67-3P
	332178-68-4P	332178-69-5P	332178-70-8P
	332178-71-9P	332178-72-0P	332178-74-2P
	332178-76-4P	332178-77-5P	332178-78-6P
	332178-79-7P	332178-82-2P	332178-83-3P
	332178-84-4P	332178-85-5P	332178-86-6P
	332178-87-7P	332178-88-8P	332178-89-9P
	332178-90-2P	332178-91-3P	332178-92-4P
	332178-93-5P	332178-94-6P	332178-95-7P
	332178-96-8P	332178-97-9P	332178-98-0P
	332178-99-1P	332179-00-7P	332179-01-8P
	332179-02-9P	332179-03-0P	332179-04-1P
	332179-05-2P	332179-06-3P	332179-07-4P
	332179-08-5P	332179-09-6P	332179-10-9P
	332179-11-0P	332179-12-1P	332179-13-2P
	332179-14-3P	332179-15-4P	332179-16-5P
	332179-17-6P	332179-18-7P	332179-19-8P
	332179-20-1P	332179-21-2P	332179-22-3P
	332179-23-4P	332179-24-5P	332179-25-6P
	332179-26-7P	332179-27-8P	332179-28-9P
	332179-29-0P	332179-30-3P	332179-31-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-
 pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators
 of NPY1 receptors)

RN 332178-32-2 CAPLUS


CN 1,2-Ethanediamine, N-[3-(4-chloro-2,6-dimethylphenyl)-2,5-
 dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-
 (9CI) (CA INDEX NAME)




RN 332178-33-3 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-
 a]pyrimidin-7-yl]-N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX
 NAME)

PAGE 1-A




PAGE 2-A




RN 332178-34-4 CAPLUS
CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-35-5 CAPLUS
CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-37-7 CAPLUS
CN Benzoic acid, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]-, methyl ester (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332178-38-8 CAPLUS
CN Benzonitrile, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]-, hydrochloride (9CI)
(CA INDEX NAME)



RN 332178-39-9 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 332178-40-2 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethynylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 332178-41-3 CAPLUS

CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]-, trans- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 332178-42-4 CAPLUS


CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-

dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]-, hydrochloride,
trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332178-44-6 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 332178-45-7 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-propoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 332178-46-8 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-propoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 332178-47-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-N-[(6-methyl-2-piperidiny)methyl]- (9CI) (CA INDEX NAME)




RN 332178-48-0 CAPLUS
 CN 1-Butanol, 2-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 332178-49-1 CAPLUS
 CN 1,4-Cyclohexanediamine, N-[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-N'-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 332178-50-4 CAPLUS
CN 1,4-Cyclohexanediamine, N-[2-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-N'-ethyl- (9CI) (CA INDEX NAME)


CCNc1ccc(cc1)NCCNC2=CN=C(C)C3=C2N=CN3C4=CC(=CC=C4Cl)Cl
$$\text{OMe}$$

Page 81

PAGE 1-A




PAGE 2-A



RN 332178-52-6 CAPLUS
CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332178-53-7 CAPLUS
 CN 1,2-Propanediol, 3-[[2-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 332178-54-8 CAPLUS
 CN 1,4-Cyclohexanediamine, N-[2-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-N'-(2-methylpropyl)-

(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-55-9 CAPLUS
CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-methylethyl]amino]- (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332178-56-0 CAPLUS
 CN Cyclohexanol, 2-[[2-[[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 332178-57-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(4,4,4-trifluorobutyl)- (9CI)
 (CA INDEX NAME)



RN 332178-59-3 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2,2-trifluoroethyl)- (9CI)
 (CA INDEX NAME)




RN 332178-60-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(trifluoromethyl)cyclohexyl]-
 (9CI) (CA INDEX NAME)



RN 332178-61-7 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[4-(trifluoromethyl)cyclohexyl]-
 (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332178-62-8 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2-difluoroethyl)- (9CI) (CA INDEX NAME)




RN 332178-63-9 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-fluoro-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 332178-64-0 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-fluorocyclohexyl)- (9CI) (CA INDEX NAME)




RN 332178-65-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 332178-66-2 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 332178-67-3 CAPLUS

CN 1,2-Propanediamine, N1-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 332178-68-4 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2-methyl-3-furanyl)-(9CI) (CA INDEX NAME)




RN 332178-69-5 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 332178-70-8 CAPLUS
 CN Benzonitrile, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 332178-71-9 CAPLUS
 CN Benzenemethanol, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]-α,α-dimethyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332178-72-0 CAPLUS
 CN 1,2-Ethanediamine, N-[3-[2,6-dichloro-4-(1-cyclopenten-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)

Cc1ccc(Cl)c(Cl)c1C2=CN(C(=N2)C3=CC(=CC=C3)C)C(=N3C=CC(=C3)C)NCCNCCO4CCCCO4


Page 94




RN 332178-76-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2-methyl-3-furanyl)- (9CI) (CA INDEX NAME)




RN 332178-77-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-(1,1-dimethylethyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 332178-78-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI)
 (CA INDEX NAME)




RN 332178-79-7 CAPLUS
 CN 1,2-Ethanediamine, N-3-cyclohexen-1-yl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 332178-82-2 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-3-piperidiny)- (9CI) (CA INDEX NAME)




RN 332178-83-3 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(phenylmethyl)-3-pyrrolidiny)- (9CI) (CA INDEX NAME)



RN 332178-84-4 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 332178-85-5 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-86-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(phenylmethyl)-4-piperidinyl]-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-87-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-methyl-4-piperidiny)- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-88-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-4-piperidinyll)-(9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-89-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-90-2 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332178-91-3 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-3-piperidiny)- (9CI)
 (CA INDEX NAME)




RN 332178-92-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-4-piperidiny- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 332178-93-5 CAPLUS
 CN 1,2-Propanediamine, N1-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 332178-94-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(3-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-95-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(4-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332178-96-8 CAPLUS
CN Phenol, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(1-phenyl-3-pyrrolidinyl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)


Cc1cc(Cl)c(Cl)cc1-c2nc3c(ncn3C)cc(C)c2NCCNCC4CCCN4c5ccccc5
$$\begin{array}{c} \diagdown \\ \text{OH} \end{array}$$

Page 109


N#CCCCN1CCCCC1CN2C=CC=CC=C2Cc1nc2c(ncn2C)c3cc(Cl)c(Cl)cc3OC

Page 110

PAGE 1-A




PAGE 2-A




RN 332178-99-1 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-00-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-01-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(phenylmethyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-02-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-03-0 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2-methyl-5-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332179-04-1 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,4-dichlorophenyl)-2-methyl-5-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-05-2 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-06-3 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-methoxyphenyl)-2-methyl-5-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-07-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-08-5 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-methoxyphenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-09-6 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-methoxyphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-10-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-11-0 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichlorophenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-12-1 CAPLUS
 CN 1,2-Propanediamine, N1-[3-(2,6-dichlorophenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-13-2 CAPLUS
 CN 1,2-Ethanediamine, N-[5-ethyl-2-methyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-14-3 CAPLUS
CN 1,2-Propanediamine, N1-[5-ethyl-2-methyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-15-4 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethynylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-16-5 CAPLUS
 CN 1,2-Ethanediamine, N-[2-methyl-5-propyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-17-6 CAPLUS
CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-18-7 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dimethylphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-19-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dimethylphenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332179-20-1 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dimethylphenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)




RN	332179-21-2	CAPLUS
CN	1,2-Propanediamine, N1-[3-(2,6-dimethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A



RN 332179-22-3 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,4-dimethylphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332179-23-4 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,4-dimethylphenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332179-24-5 CAPLUS
CN 4-Piperidinamine, 1-acetyl-N-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 332179-25-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-26-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(3-ethoxy-4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 332179-27-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 332179-28-9 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 332179-29-0 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-30-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(3-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 332179-31-4 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)




IT	332179-70-1 332179-74-5
	RL: RCT (Reactant); RACT (Reactant or reagent)
	(preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)
RN	332179-70-1 CAPLUS
CN	1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 332179-74-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




IT 332179-38-1P 332179-42-7P 332179-43-8P
 332179-55-2P 332179-56-3P 332179-57-4P
 332179-58-5P 332179-59-6P 332179-60-9P
 332179-66-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)
 RN 332179-38-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(4-chloro-2,6-dimethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332179-42-7 CAPLUS
 CN Benzeneacetamide, N-[2-[[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-4-methoxy-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-43-8 CAPLUS
 CN Benzeneacetamide, N-[2-[[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-4-ethoxy-3-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-55-2 CAPLUS
CN Benzoic acid, 3,5-dichloro-4-[7-[[2-[[[(1,1-dimethylethoxy)carbonyl](tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332179-56-3 CAPLUS
CN Carbamic acid, [2-[[3-(2,6-dichloro-4-cyanophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 332179-57-4 CAPLUS
 CN Carbamic acid, [2-[[3-(2,6-dichloro-4-ethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 332179-58-5 CAPLUS
 CN Carbamic acid, [2-[[3-(2,6-dichloro-4-hydroxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 332179-59-6 CAPLUS
 CN Carbamic acid, [2-[[3-[2,6-dichloro-4-[(methylsulfonyl)oxy]phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A






RN 332179-60-9 CAPLUS

CN Carbamic acid, [2-[[3-[2,6-dichloro-4-[(trimethylsilyl)ethynyl]phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 332179-66-5 CAPLUS

CN Phenol, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]-, hydrobromide (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; X = N, CR14; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl which optionally forms (un)substituted aminocarbocycle or aminoheterocycle with A and B, etc.; R2 and R6 with 2 N atoms to which they are bound, form (un)substituted aminoheterocycle; R2 and A form (un)substituted aminocarbocycle, aminoheterocycle; A, B = (un)substituted alkyl; A and B form (un)substituted carbocycle; B and R6 form (un)substituted aminocarbocycle; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl; R5 = (un)substituted (cycloalkyl)alkyl, alkenyl, alkynyl, etc.; R6 = H, alkyl, cycloalkyl, etc.; R14 = H, alkyl, etc.] which are selective modulators of NPY1 receptors, and are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension, were

prepared E.g., a multi-step synthesis of the pyrazolo[1,5-a]pyrimidine II, was described. The NPY1 binding affinity for the compds. I, expressed as a K_i value, ranges from 0.1 nM to 10 μ M. Compds. I are also useful as probes for the localization of NPY1 receptors and as stds. in assays for NPY1 receptor binding. Methods of using the compds. I in receptor localization studies are given.

L5 ANSWER 17 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:185043 CAPLUS

DOCUMENT NUMBER: 134:217215

TITLE: Use of CRF antagonists and related compositions for modifying circadian rhythm and treatment of depression and other conditions

INVENTOR(S): Chen, Yuhpyng Liang

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 29 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1082960	A2	20010314	EP 2000-307074	20000818 <--
EP 1082960	A3	20020320		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6432989	B1	20020813	US 2000-587007	20000605 <--
EP 1449532	A1	20040825	EP 2004-12293	20000818 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2001097889	A	20010410	JP 2000-251836	20000823 <--
HU 200003386	A2	20010730	HU 2000-3386	20000824 <--
ZA 2000004362	A	20020225	ZA 2000-4362	20000824 <--
CA 2316662	A1	20010227	CA 2000-2316662	20000825 <--
NZ 506562	A	20020927	NZ 2000-506562	20000825 <--
AU 776077	B2	20040826	AU 2000-53644	20000825 <--
US 2002156089	A1	20021024	US 2002-161816	20020604 <--
US 2004082597	A1	20040429	US 2003-676201	20031001 <--
PRIORITY APPLN. INFO.:			US 1999-151183P	P 19990827 <--
			US 2000-587007	A3 20000605 <--
			EP 2000-307074	A3 20000818 <--
			US 2002-161816	A3 20020604 <--


IT 202579-62-2 202579-64-4 203924-40-7
203924-41-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(CRF antagonists and related compns. for modifying circadian rhythm and treatment of depression and other conditions, and use with other agents)

RN 202579-62-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 203924-40-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 203924-41-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-5-methyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



AB A corticotropin releasing factor (CRF) antagonist is administered to treat disorders that can be treated by altering circadian rhythm, as well as depression (in which a second compound for treating depression is administered, the second compound having an onset of action that is delayed with respect to that of the CRF antagonist). Methods for treating cardiovascular diseases, migraine, non-migraine headaches, and emesis are also disclosed.

L5 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:131201 CAPLUS
 DOCUMENT NUMBER: 134:178572
 TITLE: Preparation of azolo triazines and pyrimidines as
 corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis,
 Argyrios Georgios
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Co., USA
 SOURCE: U.S., 90 pp., Cont.-in-part of U. S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6191131	B1	20010220	US 1998-15002	19980128 <--
CA 2532925	A1	19980129	CA 1997-2532925	19970723 <--
US 6124289	A	20000926	US 1997-899242	19970723 <--
ZA 9706603	A	19990125	ZA 1997-6603	19970724 <--
US 6136809	A	20001024	US 1998-14999	19980128 <--
LT 4680	B	20000725	LT 1999-8	19990125 <--
CA 2314613	A1	19990805	CA 1999-2314613	19990128 <--
WO 9938868	A1	19990805	WO 1999-US1824	19990128 <--
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9924787	A	19990816	AU 1999-24787	19990128 <--
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128 <--
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128 <--
JP 2002501922	T	20020122	JP 2000-529335	19990128 <--
NZ 505079	A	20030829	NZ 1999-505079	19990128 <--
EP 1344779	A1	20030917	EP 2003-75887	19990128 <--
EP 1344779	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 264860	T	20040515	AT 1999-904382	19990128 <--
PT 1049699	T	20040831	PT 1999-904382	19990128 <--
CN 1542010	A	20041103	CN 2003-10122546	19990128 <--
ES 2218991	T3	20041116	ES 1999-904382	19990128 <--
SG 111076	A1	20050530	SG 2002-200204556	19990128 <--
AT 301657	T	20050815	AT 2003-75887	19990128 <--
PT 1344779	T	20051031	PT 2003-75887	19990128 <--
ES 2247478	T3	20060301	ES 2003-75887	19990128 <--
TW 520372	B	20030211	TW 1999-88102636	19990223 <--
US 6358950	B1	20020319	US 2000-696759	20001026 <--
HK 1060348	A1	20051021	HK 2004-101985	20040317 <--
JP 2005097257	A	20050414	JP 2004-216483	20040723 <--
PRIORITY APPLN. INFO.:			US 1996-23290P	P 19960724 <--
			US 1997-899242	A2 19970723 <--
			US 1996-686047	A 19960724 <--
			CA 1997-2259583	A3 19970723 <--
			JP 1998-507233	A3 19970723 <--

US 1998-14734	A	19980128	<--
US 1998-15001	A	19980128	<--
US 1998-15002	A	19980128	<--
EP 1999-904382	A3	19990128	<--
WO 1999-US1824	W	19990128	<--


OTHER SOURCE(S): MARPAT 134:178572

IT 202579-57-5P 202579-60-0P 202579-62-2P
 202579-63-3P 202579-64-4P 202579-65-5P
 202579-69-9P 202579-73-5P 202579-74-6P
 202579-75-7P 202579-77-9P 202579-78-0P
 202579-80-4P 202579-81-5P 202579-82-6P
 202579-84-8P 202579-87-1P 202579-91-7P
 202579-92-8P 202579-94-0P 202579-95-1P
 202580-25-4P 202580-26-5P 202580-28-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolo-fused triazines and pyrimidines as CRF antagonists)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-65-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-69-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-75-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-78-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-82-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-87-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)





RN 202580-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR2; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, alk(en/yn)yl, halo, etc.; R1, R2 = H, alk(en/yn)yl, halo, etc.; R3 = H, SH, aryl, etc.; R14 = (un)substituted

alk(en/yn)yl, cycloalkyl(alkyl)], useful in treating CRF-related disorders, particularly anxiety, depression, and other psychiatric, neurol. disorders as well as treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. For instance, 5-amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole was cyclized with Et acetoacetate in AcOH to give 42% 7-hydroxy-2,5-dimethyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine. The latter was treated with POCl₃ and PhNEt₂ to give the 7-chloro analog (84%), which reacted with 3-pentylamine to give 60% title compound I [A = CH; R₁ = Me; R₃ = NHCH₂Et; Z = CMe; Ar = 2-Cl-4-MeC₆H₃]. The compds. I are effective at 0.002-200 mg/kg/day.

REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:307132 CAPLUS
 DOCUMENT NUMBER: 132:321873
 TITLE: Azolo triazines and pyrimidines useful as
 corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): Gilligan, Paul; Chorvat, Robert; Arvanitis, Argyrios
 Georgios
 PATENT ASSIGNEE(S): DuPont Pharmaceuticals Co., USA
 SOURCE: U.S., 86 pp., Cont.-in-part of U.S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6060478	A	20000509	US 1998-15001	19980128 <--
CA 2532925	A1	19980129	CA 1997-2532925	19970723 <--
US 6124289	A	20000926	US 1997-899242	19970723 <--
ZA 9706603	A	19990125	ZA 1997-6603	19970724 <--
US 6136809	A	20001024	US 1998-14999	19980128 <--
LT 4680	B	20000725	LT 1999-8	19990125 <--
CA 2314613	A1	19990805	CA 1999-2314613	19990128 <--
WO 9938868	A1	19990805	WO 1999-US1824	19990128 <--
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9924787	A	19990816	AU 1999-24787	19990128 <--
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128 <--
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128 <--
JP 2002501922	T	20020122	JP 2000-529335	19990128 <--
NZ 505079	A	20030829	NZ 1999-505079	19990128 <--
EP 1344779	A1	20030917	EP 2003-75887	19990128 <--
EP 1344779	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 264860	T	20040515	AT 1999-904382	19990128 <--
PT 1049699	T	20040831	PT 1999-904382	19990128 <--
CN 1542010	A	20041103	CN 2003-10122546	19990128 <--
ES 2218991	T3	20041116	ES 1999-904382	19990128 <--
SG 111076	A1	20050530	SG 2002-200204556	19990128 <--
AT 301657	T	20050815	AT 2003-75887	19990128 <--
PT 1344779	T	20051031	PT 2003-75887	19990128 <--
ES 2247478	T3	20060301	ES 2003-75887	19990128 <--
TW 520372	B	20030211	TW 1999-88102636	19990223 <--
HK 1060348	A1	20051021	HK 2004-101985	20040317 <--
JP 2005097257	A	20050414	JP 2004-216483	20040723 <--
PRIORITY APPLN. INFO.:				
			US 1996-23290P	P 19960724 <--
			US 1997-899242	A2 19970723 <--
			US 1996-686047	A 19960724 <--
			CA 1997-2259583	A3 19970723 <--
			JP 1998-507233	A3 19970723 <--
			US 1998-14734	A 19980128 <--

US 1998-15001	A	19980128	<--
US 1998-15002	A	19980128	<--
EP 1999-904382	A3	19990128	<--
WO 1999-US1824	W	19990128	<--

OTHER SOURCE(S): MARPAT 132:321873

IT 202579-57-5P 202579-60-0P 202579-62-2P
202579-63-3P 202579-64-4P 202579-65-5P
202579-69-9P 202579-73-5P 202579-74-6P
202579-75-7P 202579-77-9P 202579-78-0P
202579-80-4P 202579-81-5P 202579-82-6P
202579-84-8P 202579-87-1P 202579-91-7P
202579-92-8P 202579-94-0P 202579-95-1P
202580-25-4P 202580-26-5P 202580-28-7P
202580-53-8P 202580-54-9P 202580-56-1P
202580-57-2P 202580-58-3P 202580-59-4P
234776-70-6P 234776-71-7P 234776-75-1P
234776-76-2P 234776-80-8P 234776-81-9P
234776-82-0P 234776-83-1P 234776-84-2P
234776-86-4P 234776-87-5P 234776-88-6P
234776-89-7P 234776-90-0P 234776-93-3P
234776-94-4P 234776-98-8P 234776-99-9P
234777-00-5P 234777-01-6P 234777-03-8P
234777-06-1P 234777-08-3P 234777-11-8P
234777-12-9P 234777-13-0P 234777-14-1P
234777-15-2P 234777-16-3P 234777-20-9P
234777-21-0P 234777-25-4P 234777-26-5P
234777-27-6P 234777-28-7P 234777-29-8P
234777-31-2P 234777-32-3P 234777-33-4P
234777-34-5P 234777-35-6P 234777-38-9P
234777-39-0P 234777-44-7P 234777-45-8P
234777-46-9P 234777-47-0P 234777-49-2P
234777-52-7P 234777-54-9P 234777-57-2P
234777-58-3P 234777-59-4P 234777-60-7P
234777-61-8P 234777-62-9P 234777-66-3P
234777-67-4P 234777-71-0P 234777-72-1P
234777-73-2P 234777-74-3P 234777-75-4P
234777-77-6P 234777-78-7P 234777-79-8P
234777-80-1P 234777-81-2P 234777-84-5P
234777-85-6P 234777-89-0P 234777-90-3P
234777-91-4P 234777-92-5P 234777-94-7P
234777-97-0P 234777-99-2P 234778-02-0P
234778-03-1P 234778-04-2P 234778-07-5P
234778-08-6P 234778-09-7P 234778-10-0P
234778-11-1P 234778-12-2P 234778-15-5P
234778-16-6P 234778-17-7P 234778-18-8P
234778-19-9P 234778-20-2P 234778-23-5P
234778-24-6P 234778-25-7P 234778-26-8P
234778-27-9P 234778-28-0P 234778-31-5P
234778-32-6P 234778-33-7P 234778-34-8P
234778-35-9P 234778-36-0P 234778-39-3P
234778-40-6P 234778-41-7P 234778-42-8P
234778-43-9P 234778-44-0P 234778-47-3P
234778-48-4P 234778-49-5P 234778-50-8P
234778-51-9P 234778-52-0P 235083-80-4P
267233-61-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of azolo-fused triazines and pyrimidines as

CRF

antagonists)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-65-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-69-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-78-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-82-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-87-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-53-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 202580-54-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-56-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-57-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-70-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234776-71-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-75-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-76-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-80-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-81-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-82-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-83-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 234776-84-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-86-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-87-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234776-88-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-
[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-89-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-
[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 234776-90-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-
[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-93-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234776-94-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-98-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-99-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-00-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-6-chloro-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-01-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-chloro-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-03-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-chloro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-06-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-08-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-11-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-12-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-(1-ethoxypropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-13-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-14-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-15-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-2,5,6-trimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234777-16-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-20-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-21-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-27-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-28-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 234777-29-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-31-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-32-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-2,5,6-trimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234777-33-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-34-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234777-35-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-38-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-39-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-44-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-45-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-46-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-47-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-49-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-52-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-54-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-57-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-60-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-61-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-62-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-66-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-67-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-71-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-72-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-73-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-74-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-75-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-77-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-78-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234777-79-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-80-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234777-81-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-84-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 234777-85-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-

[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-89-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-90-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-91-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-92-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-94-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-97-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-99-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-02-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-6-fluoro-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-03-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-04-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-07-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-08-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-ethyl-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-09-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-10-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-6-chloro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-11-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-12-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-15-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-16-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-17-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-18-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)



RN 234778-19-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-20-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-23-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-24-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-6-fluoro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-25-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-26-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-6-fluoro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-27-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-28-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-31-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-32-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-33-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-34-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)



RN 234778-35-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-36-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-39-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-40-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-41-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-42-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2-methylphenyl)-
 N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)



RN 234778-43-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5,6-
 trimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-44-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2-
 methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-49-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-50-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-51-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-52-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 235083-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)






RN 267233-61-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI



AB Corticotropin releasing factor (CRF) antagonists (no data) of formulas I and II are disclosed [wherein A = N or CR; Z = N or CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, pyrimidinyl, indanyl, tetralinyl, addnl. selected heterocycles; R = H, alk(en/yn)yl, cycloalkyl(alkyl), halo, cyano, haloalkyl; R₁, R₂ = H, groups listed for R, NH₂ or derivs., OH or derivs., SH or derivs., addnl. substituted alkyls; R₃ = H, OH or derivs., SH or derivs., acyl, CO₂H or esters, NH₂ or derivs., aryl, heteroaryl, alk(en/yn)yl, etc.; R₄ = (un)substituted alk(en/yn)yl or cycloalkyl(alkyl)]. The compds. are of use in the treatment of CRF-related disorders, particularly anxiety and depression, as well as other psychiatric, neurol., immunol., cardiovascular, and psychopathol. disorders. For instance, 5-amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole was cyclized with Et acetoacetate in AcOH to give 42% 7-hydroxy-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine. The latter was treated with POCl₃ and PhNEt₂ to give the 7-chloro analog (84%), which reacted with 3-pentylamine to give 60% title compound III.

REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:125866 CAPLUS

DOCUMENT NUMBER: 132:231516

TITLE: The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist

AUTHOR(S): Gilligan, Paul J.; Baldauf, Caryn; Cocuzza, Anthony; Chidester, Dennis; Zaczek, Robert; Fitzgerald, Lawrence W.; McElroy, John; Smith, Mark A.; Shen, H.-S. L.; Saye, Jo Anne; Christ, David; Trainor, George; Robertson, David W.; Hartig, Paul

CORPORATE SOURCE: Chemical and Physical Sciences Department, Experimental Station, DuPont Pharmaceuticals Co., Wilmington, DE, 10880-0500, USA

SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(1), 181-189

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 202579-74-6P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (structure-activity relationships of pyrazolo-[1,5-a]-pyrimidines as human CRF1 antagonists leading to discovery of anxiolytic DMP904)

RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



IT 202579-60-0 202579-62-2 202579-63-3

202579-75-7 202579-91-7 202579-94-0

202579-95-1 202580-25-4 202580-28-7


262298-00-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(structure-activity relationships of pyrazolo-[1,5-a]-pyrimidines as human CRF1 antagonists leading to discovery of anxiolytic DMP904)


RN 202579-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethoxypropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-28-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 262298-00-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethoxypropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




IT 202579-57-5P 202579-64-4P 202579-65-5P
 202579-69-9P 202579-73-5P 202579-80-4P
 202579-81-5P 202579-82-6P 202579-92-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (structure-activity relationships of pyrazolo-[1,5-a]-pyrimidines as human CRF1 antagonists leading to discovery of anxiolytic DMP904)
 RN 202579-57-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-65-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-69-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-82-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



AB Structure-activity relationship studies led to the discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (compound 11-31, DMP904), whose pharmacol. profile strongly supports the hypothesis that hCRF1 antagonists may be potent anxiolytic drugs. Compound 11-31 (hCRF1 $K_i = 1.0 \pm 0.2$ nM ($n = 8$)) was a potent antagonist of hCRF1-coupled adenylate cyclase activity in HEK293 cells ($IC_{50} = 10.0 \pm 0.01$ nM vs. 10 nM r/hCRF, $n = 8$); α -helical CRF(9-41) had weaker potency ($IC_{50} = 286 \pm 63$ nM, $n = 3$). Analog 11-31 had good oral activity in the rat situational anxiety test; the min. ED for 11-31 was 0.3 mg/kg, orally. Maximal efficacy (approx. 57% reduction in latency time in the dark compartment) was observed at this dose. Chlordiazepoxide caused a 72% reduction in latency at 20 mg/kg, orally. CP154526-1 (30 mg/kg, orally) was inactive in this test. Compound 11-31 did not inhibit open-field locomotor activity at 10, 30, and 100 mg/kg, orally

in rats. In beagle dogs, this compound (5 mg/kg, i.v., orally) afforded good plasma levels. The key i.v. pharmacokinetic parameters were $t_{1/2}$, CL and $V_{d,ss}$ values equal to 46.4 ± 7.6 h, 0.49 ± 0.08 L/kg/h and 23.0 ± 4.2 L/kg, resp. After oral dosing, the mean C_{max} , T_{max} , $t_{1/2}$ and bioavailability values were equal to 1260 ± 290 nM, 0.75 ± 0.25 h, 45.1 ± 10.2 h and 33.1%, resp. The overall rat behavioral profile of this compound suggests that it may be an anxiolytic drug with a low motor side effect liability.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:495296 CAPLUS
DOCUMENT NUMBER: 131:144616
TITLE: Preparation of azolotriazines and -pyrimidines as
corticotropin releasing factor (CRF) antagonists
INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis,
Argyrios Georgios
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938868	A1	19990805	WO 1999-US1824	19990128 <--
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6060478	A	20000509	US 1998-15001	19980128 <--
US 6191131	B1	20010220	US 1998-15002	19980128 <--
US 6313124	B1	20011106	US 1998-14734	19980128 <--
CA 2314613	A1	19990805	CA 1999-2314613	19990128 <--
AU 9924787	A	19990816	AU 1999-24787	19990128 <--
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128 <--
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128 <--
JP 2002501922	T	20020122	JP 2000-529335	19990128 <--
NZ 505079	A	20030829	NZ 1999-505079	19990128 <--
AT 264860	T	20040515	AT 1999-904382	19990128 <--
ZA 9900843	A	20000802	ZA 1999-843	19990203 <--
MX 2000PA06495	A	20011011	MX 2000-PA6495	20000629 <--
AU 2002300983	A1	20030220	AU 2002-300983	20020911 <--
PRIORITY APPLN. INFO.:			US 1998-14734	A 19980128 <--
			US 1998-15001	A 19980128 <--
			US 1998-15002	A 19980128 <--
			US 1996-23290P	P 19960724 <--
			US 1997-899242	A2 19970723 <--
			AU 1999-24787	A3 19990128 <--
			WO 1999-US1824	W 19990128 <--
IT 202579-57-5P 234776-70-6P 234776-71-7P				
234776-75-1P 234776-76-2P 234776-80-8P				
234776-81-9P 234776-82-0P 234776-83-1P				
234776-84-2P 234776-86-4P 234776-87-5P				
234776-88-6P 234776-89-7P 234776-90-0P				
234776-93-3P 234776-94-4P 234776-98-8P				
234776-99-9P 234777-00-5P 234777-01-6P				
234777-03-8P 234777-06-1P 234777-08-3P				
234777-11-8P 234777-12-9P 234777-13-0P				
234777-14-1P 234777-15-2P 234777-16-3P				
234777-20-9P 234777-21-0P 234777-25-4P				
234777-26-5P 234777-27-6P 234777-28-7P				
234777-29-8P 234777-31-2P 234777-32-3P				

234777-33-4P 234777-34-5P 234777-35-6P
 234777-38-9P 234777-39-0P 234777-44-7P
 234777-45-8P 234777-46-9P 234777-47-0P
 234777-49-2P 234777-52-7P 234777-54-9P
 234777-57-2P 234777-58-3P 234777-59-4P
 234777-60-7P 234777-61-8P 234777-62-9P
 234777-66-3P 234777-67-4P 234777-71-0P
 234777-72-1P 234777-73-2P 234777-74-3P
 234777-75-4P 234777-77-6P 234777-78-7P
 234777-79-8P 234777-80-1P 234777-81-2P
 234777-84-5P 234777-85-6P 234777-89-0P
 234777-90-3P 234777-91-4P 234777-92-5P
 234777-94-7P 234777-97-0P 234777-99-2P
 234778-02-0P 234778-03-1P 234778-04-2P
 234778-07-5P 234778-08-6P 234778-09-7P
 234778-10-0P 234778-11-1P 234778-12-2P
 234778-15-5P 234778-16-6P 234778-17-7P
 234778-18-8P 234778-19-9P 234778-20-2P
 234778-23-5P 234778-24-6P 234778-25-7P
 234778-26-8P 234778-27-9P 234778-28-0P
 234778-31-5P 234778-32-6P 234778-33-7P
 234778-34-8P 234778-35-9P 234778-36-0P
 234778-39-3P 234778-40-6P 234778-41-7P
 234778-42-8P 234778-43-9P 234778-44-0P
 234778-47-3P 234778-48-4P 234778-49-5P
 234778-50-8P 234778-51-9P 234778-52-0P
 235083-80-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolotriazines and -pyrimidines as CRF antagonists for treatment of anxiety, depression, and other psychiatric, neurol. disorders)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-70-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234776-71-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-75-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-76-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-80-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-81-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-82-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-83-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 234776-84-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-86-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-87-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234776-88-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-
[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-89-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-
[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 234776-90-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-
[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-93-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234776-94-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-98-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-99-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-00-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-6-chloro-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-01-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-chloro-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-03-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-chloro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-06-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-08-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-11-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-12-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-(1-ethoxypropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-13-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-14-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-15-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-2,5,6-trimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234777-16-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-20-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-21-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-27-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-28-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 234777-29-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-31-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-32-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-2,5,6-trimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234777-33-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-34-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-35-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-38-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-39-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-44-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-45-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-46-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-47-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-49-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-52-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-54-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-57-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-60-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-61-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-62-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-66-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-67-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-71-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-72-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-73-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-74-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-75-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-77-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-78-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234777-79-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(2-methoxy-1-(methoxymethyl)ethyl)]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-80-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234777-81-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-84-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 234777-85-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-

[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-89-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-90-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-91-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-92-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-94-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-97-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-99-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-02-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-6-fluoro-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-03-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-04-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-07-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-08-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-ethyl-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-09-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-10-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-6-chloro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-11-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-12-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-15-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)



RN 234778-16-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-17-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-18-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-19-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-20-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-23-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-24-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-6-fluoro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-25-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-26-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-6-fluoro-3-(4-methoxy-2-methylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-27-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-28-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-31-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-32-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-33-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-34-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)



RN 234778-35-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-36-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-39-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-40-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-41-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl-N-propyl- (9CI) (CA INDEX NAME)




RN	234778-42-8	CAPLUS
CN	Pyrrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)	



RN	234778-43-9	CAPLUS
CN	Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)	




RN	234778-44-0	CAPLUS
CN	Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)	




RN 234778-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-49-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 234778-50-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (9CI) (CA INDEX NAME)




RN 234778-51-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-52-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)





RN 235083-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR2; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, C1-4 alkyl, C2-4 alkenyl, etc.; R1 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R2 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R3 = H, SH, OH, etc.; R14 = C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists (no data) which are useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POCl3 and N,N-dimethylaniline, followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxy-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R1 = Me; R3 = NHCH(CH2OMe)2; Ar = 2,4-Cl2C6H3].

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:467208 CAPLUS

DOCUMENT NUMBER: 131:237490

TITLE: Synthesis and structure-activity relationship of a new series of potent angiotensin II receptor antagonists: pyrazolo[1,5-a]pyrimidine derivatives

AUTHOR(S): Shiota, Takeshi; Yamamori, Teruo; Sakai, Katsunori; Kiyokawa, Mitsugu; Honma, Tsunetoshi; Ogawa, Masayoshi; Hayashi, Kunio; Ishizuka, Natsuki; Matsumura, Ken-Ichi; Hara, Mariko; Fujimoto, Masafumi; Kawabata, Tomoji; Nakajima, Shigeyuki

CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi and Co., Ltd., Osaka, 553-0002, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1999), 47(7), 928-938

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 244127-04-6P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(synthesis and structure-activity relationship of pyrazolo[1,5-a]pyrimidines as angiotensin II receptor antagonists)

RN 244127-04-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-ethyl-3-phenyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




IT 244127-51-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and structure-activity relationship of pyrazolo[1,5-a]pyrimidines as angiotensin II receptor antagonists)

RN 244127-51-3 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[[5-ethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]methyl]- (9CI) (CA INDEX NAME)



AB We have already reported 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid derivs., which are potent in vitro angiotensin II (AII) antagonists, but have no oral antihypertensive activity. Removal of the carboxylic acid and replacement of the heteroarom. system afforded potent in vitro antagonists. Removal of the carbonyl oxygen and changing the position of the biphenyltetrazole substituent were critical to the display of oral activity. To improve the in vitro and oral activities, modifications were made of the substituents at the 3- and 5- positions of the pyrazolo[1,5-a]pyrimidine. Structure-activity studies showed the Me substituent at the 3-position to be essential for potent in vivo activity. We present the design, syntheses, and biol. data of a series of pyrazolo[1,5-a]pyrimidine derivs., which are orally active AII receptor antagonists.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:606868 CAPLUS

DOCUMENT NUMBER: 129:302612

TITLE: Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists

AUTHOR(S): Wustrow, David J.; Capiris, Thomas; Rubin, Ronald;
Knobelsdorf, A.; Akunne, Hyacinth; Davis, M. Duff;
MacKenzie, Robert; Pugsley, Thomas A.; Zoski, Kim T.;
Heffner, Thomas G.; Wise, Lawrence D.

CORPORATE SOURCE: Parke-Davis Pharmaceutical Research, Division of
Warner-Lambert Company, Ann Arbor, MI, 48105, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1998
, 8(16), 2067-2070

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 214416-28-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)

(preparation of pyrazolo[1,5-a]pyrimidines and their affinity for the human
CRF-1 receptor)

RN 214416-28-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-2,5-
dimethyl- (9CI) (CA INDEX NAME)



AB A series of pyrazolo[1,5-a]pyrimidines was prepared and found to have
affinity for the human CRF-1 receptor. The 3-dimensional structure of one
of the most potent analogs in this series was determined by X-ray crystallog.
and suggests the spatial requirements for potent CRF-1 receptor binding
affinity in this series.


REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1998:246630 CAPLUS
DOCUMENT NUMBER: 128:248613
TITLE: Adenosine reinforcement agents
INVENTOR(S): Moritoki, Hideki; Iwamoto, Takeshi; Yasuda, Tsuneo
PATENT ASSIGNEE(S): Ootsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 10101672	A	19980421	JP 1997-208772	19970804 <--


PRIORITY APPLN. INFO.: JP 1996-207171 A 19960806 <--
OTHER SOURCE(S): MARPAT 128:248613
IT 174859-38-2 174859-40-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine reinforcement agents)
RN 174859-38-2 CAPLUS
CN Benzamide, N-[5-butyl-2-phenyl-3-[4-(phenylthio)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 174859-40-6 CAPLUS
CN Benzamide, N-(5-butyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



GI




AB The title compds. [I; R1 = H, lower alkoxy or alkylthio, oxo, etc.; R2 = naphthyl, cycloalkyl, (un)substituted phenoxy, etc.; R3 = H, Ph, lower alkyl; R4 = H, lower alkyl, halo, aralkyl, etc.; R5 = H, lower alkyl; R6 = H, lower alkyl, (un)substituted benzoyl, etc.; Q = CO, SO₂; A = single bond, lower alkylene or alkenylene; n = 0, 1] are presented as adenosine reinforcement agents. I, possessing adenosine reinforcement activity, are useful for prevention and treatment of heart attack, myocardial and brain infarction. Ten compds. of I were tested and showed excellent adenosine reinforcement activity. Formulation containing I were also prepared

L5 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1998:246629 CAPLUS
DOCUMENT NUMBER: 128:248612
TITLE: Nitrogen monooxide synthase inhibitors
INVENTOR(S): Moritoki, Hideki; Iwamoto, Takeshi; Yasuda, Tsuneo
PATENT ASSIGNEE(S): Ootsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 10101671	A	19980421	JP 1997-207867	19970801 <--


PRIORITY APPLN. INFO.: JP 1996-209465 A 19960808 <--
OTHER SOURCE(S): MARPAT 128:248612
IT 174859-38-2 174859-40-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyroazolopyrimidine derivs. as nitrogen monooxide synthase inhibitors)
RN 174859-38-2 CAPLUS
CN Benzamide, N-[5-butyl-2-phenyl-3-[4-(phenylthio)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 174859-40-6 CAPLUS
CN Benzamide, N-(5-butyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = H, lower alkoxy or alkylthio, oxo, etc.; R2 = naphthyl, cycloalkyl, (un)substituted phenoxy, etc.; R3 = H, Ph, lower alkyl; R4 = H, lower alkyl, halo, aralkyl, etc.; R5 = H, lower alkyl; R6 = H, lower alkyl, (un)substituted benzoyl, etc.; Q = CO, SO₂; A = single bond, lower alkylene or alkenylene; n = 0, 1] are presented as NO synthase inhibitors. I are useful for prevention and treatment of septicemia. 14 Compds. of I were tested and showed excellent NO synthase inhibitory activity. Formulation containing I were also prepared

L5 ANSWER 26 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1998:163594 CAPLUS
DOCUMENT NUMBER: 128:204902
TITLE: Preparation of heterobicyclic derivatives as CRF antagonists
INVENTOR(S): Chen, Yuhpyng Liang
PATENT ASSIGNEE(S): Pfizer Inc., USA; Chen, Yuhpyng Liang
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808847	A1	19980305	WO 1997-IB922	19970725 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2263566	A1	19980305	CA 1997-2263566	19970725 <--
CA 2263566	C	20030909		
AU 9734561	A	19980319	AU 1997-34561	19970725 <--
AU 735401	B2	20010705		
EP 923582	A1	19990623	EP 1997-930697	19970725 <--
EP 923582	B1	20060920		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9711970	A	19990824	BR 1997-11970	19970725 <--
CN 1227554	A	19990901	CN 1997-197027	19970725 <--
JP 2000502723	T	20000307	JP 1998-511429	19970725 <--
JP 3621706	B2	20050216		
TR 9900389	T2	20000621	TR 1999-389	19970725 <--
NZ 333302	A	20000825	NZ 1997-333302	19970725 <--
AT 340176	T	20061015	AT 1997-930697	19970725 <--
ES 2273369	T3	20070501	ES 1997-930697	19970725 <--
HR 970454	B1	20021031	HR 1997-454	19970822 <--
TW 575573	B	20040211	TW 1997-86112194	19970825 <--
IN 1997DE02410	A	20050311	IN 1997-DE2410	19970826 <--
ZA 9707687	A	19990301	ZA 1997-7687	19970827 <--
NO 9900927	A	19990226	NO 1999-927	19990226 <--
NO 313636	B1	20021104		
KR 2000035934	A	20000626	KR 1999-701674	19990227 <--
US 2001007867	A1	20010712	US 1999-242682	19991213 <--
US 2002151713	A1	20021017	US 2002-160206	20020530 <--
US 6900217	B2	20050531		
US 2005009823	A1	20050113	US 2004-762742	20040122 <--
JP 2005047930	A	20050224	JP 2004-273978	20040921 <--
PRIORITY APPLN. INFO.:			US 1996-25039P	P 19960828 <--
			JP 1998-511429	A3 19970725 <--
			WO 1997-IB922	W 19970725 <--
			US 1999-242682	A1 19991213 <--
			US 2002-160206	A3 20020530 <--
OTHER SOURCE(S):	MARPAT	128:204902		
IT	203924-40-7P	203924-41-8P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterobicyclic derivs. as CRF antagonists)


RN 203924-40-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)





RN 203924-41-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-5-methyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; A = N or CR7; D<E = O, S, NR8, CO, CS, CR4R6; G = N or C; 1 of J,K = N and the other = C; J = K =C; R = NR1R2, COR2, CR1R2R10, etc.; R1 = (un)substituted alkyl, -alkenyl, -alkynyl, etc.; R2 = alk(en)yl, (hetero)aryl(alkyl), etc.; R3 = H, halo, alkyl, alkoxy, etc.; R4 = H, halo, alkyl, alkoxy, etc.; R5 = substituted (hetero)aryl; R6 = H, Me, Et; R7 = H, halo, alkyl, alkoxy, etc.; R8 = H or alkyl; R10 = H, OH, OMe, F] were prepared as CRF antagonists (no data). Thus, OHCCHR5CN (R5 = 2,4,6-trimethylphenyl throughout) was cyclocondensed with H2NNH2 and the pyrazole product cyclocondensed with MeCOCH2CO2Me to give

pyrazolopyrimidine II (R = OH) which was treated with POCl₃ and the
product etherified by Et₂CHOH to give II (R = OCHEt₂).
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:87733 CAPLUS
DOCUMENT NUMBER: 128:154103
TITLE: Preparation of azolotriazines and -pyrimidines as
corticotropin releasing factor (CRF) antagonists
INVENTOR(S): Arvanitis, Argyrios Georgious; Chorvat, Robert John
PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803510	A1	19980129	WO 1997-US13072	19970723 <--
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2259583	A1	19980129	CA 1997-2259583	19970723 <--
CA 2532925	A1	19980129	CA 1997-2532925	19970723 <--
AU 9738942	A	19980210	AU 1997-38942	19970723 <--
AU 747708	B2	20020523		
EP 915880	A1	19990519	EP 1997-936222	19970723 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1225637	A	19990811	CN 1997-196525	19970723 <--
CN 1104432	B	20030402		
BR 9710544	A	19990817	BR 1997-10544	19970723 <--
US 6124289	A	20000926	US 1997-899242	19970723 <--
HU 200102187	A2	20011128	HU 2001-2187	19970723 <--
HU 200102187	A3	20021228		
JP 2002513382	T	20020508	JP 1998-507233	19970723 <--
EE 4316	B1	20040615	EE 1999-19	19970723 <--
RO 121272	B1	20070228	RO 1999-78	19970723 <--
ZA 9706603	A	19990125	ZA 1997-6603	19970724 <--
TW 542827	B	20030721	TW 1997-86110640	19970725 <--
TW 238164	B	20050821	TW 2003-92105694	19970725 <--
MX 9900633	A	20020131	MX 1999-633	19990115 <--
LV 12292	B	19991120	LV 1999-13	19990120 <--
NO 9900264	A	19990310	NO 1999-264	19990121 <--
NO 315610	B1	20030929		
LT 4680	B	20000725	LT 1999-8	19990125 <--
CN 1327793	A	20011226	CN 2001-120849	20010530 <--
AU 773039	B2	20040513	AU 2002-23236	20020312 <--
CN 1388126	A	20030101	CN 2002-118589	20020425 <--
JP 2005097257	A	20050414	JP 2004-216483	20040723 <--
PRIORITY APPLN. INFO.:			US 1996-23290P	P 19960724 <--
			US 1996-686047	A 19960724 <--
			US 1997-899242	A 19970723 <--
			AU 1997-38942	A3 19970723 <--
			CA 1997-2259583	A3 19970723 <--
			JP 1998-507233	A3 19970723 <--
			WO 1997-US13072	W 19970723 <--
OTHER SOURCE(S):	MARPAT 128:154103			
IT 202579-57-5P	202579-60-0P	202579-62-2P		
202579-63-3P	202579-64-4P	202579-65-5P		
202579-69-9P	202579-73-5P	202579-74-6P		
202579-75-7P	202579-77-9P	202579-78-0P		

202579-80-4P 202579-81-5P 202579-82-6P
 202579-84-8P 202579-87-1P 202579-91-7P
 202579-92-8P 202579-94-0P 202579-95-1P
 202580-25-4P 202580-26-5P 202580-28-7P
 202580-48-1P 202580-52-7P 202580-53-8P
 202580-54-9P 202580-55-0P 202580-56-1P
 202580-57-2P 202580-58-3P 202580-59-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-62-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-65-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-69-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-78-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-82-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-87-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-48-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2,3-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-52-7 CAPLUS
 CN 1,3-Propanediol, 2-[[3-(2,4-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 202580-53-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 202580-54-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-55-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 202580-56-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-57-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)





RN 202580-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, C1-4 alkyl, C2-4 alkenyl, etc.; R₁ = H, C1-4 alkyl, C2-4 alkenyl, etc.; R₂ = H, C1-4 alkyl, C2-4 alkenyl, etc.; R₃ = H, SH, OH, etc.; R₁₄ = C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POC13 and N,N-dimethylaniline followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxypropyl-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R₁ = Me; R₃ = NHCH(CH₂OMe)₂; Ar = 2,4-C₁₂H₃].

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:542450 CAPLUS
DOCUMENT NUMBER: 127:220669
TITLE: Pyrazolopyrimidines as CRF receptor antagonists
INVENTOR(S): Chen, Chen; Webb, Thomas R.; McCarthy, James R.;
Moran, Terence J.; Wilcoxon, Keith M.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.; Neurocrine
Biosciences, Inc.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729109	A1	19970814	WO 1997-EP459	19970130 <--
W: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2233285	A1	19970814	CA 1997-2233285	19970130 <--
CA 2233285	C	20060704		
AU 9715991	A	19970828	AU 1997-15991	19970130 <--
AU 713673	B2	19991209		
EP 880523	A1	19981202	EP 1997-902295	19970130 <--
EP 880523	B1	20060816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1205009	A	19990113	CN 1997-191382	19970130 <--
CN 1090189	B	20020904		
HU 9900575	A2	19990628	HU 1999-575	19970130 <--
BR 9707391	A	19990720	BR 1997-7391	19970130 <--
NZ 330119	A	20000228	NZ 1997-330119	19970130 <--
JP 2000503661	T	20000328	JP 1997-528123	19970130 <--
JP 3356291	B2	20021216		
JP 2002121194	A	20020423	JP 2001-265611	19970130 <--
EE 4282	B1	20040415	EE 1998-124	19970130 <--
PL 191271	B1	20060428	PL 1997-327284	19970130 <--
AT 336495	T	20060915	AT 1997-902295	19970130 <--
ES 2168237	T3	20070401	ES 1997-902295	19970130 <--
IN 1998CA00198	A	20050311	IN 1998-CA198	19970203 <--
TW 449599	B	20010811	TW 1997-86101373	19970205 <--
ZA 9700989	A	19980806	ZA 1997-989	19970206 <--
NO 9801357	A	19980803	NO 1998-1357	19980325 <--
NO 310292	B1	20010618		
US 2003125341	A1	20030703	US 1999-117717	19990302 <--
US 6664261	B2	20031216		
US 2004127483	A1	20040701	US 2003-665740	20030919 <--
US 7074797	B2	20060711		
US 2006270659	A1	20061130	US 2006-413610	20060428 <--
PRIORITY APPLN. INFO.:			US 1996-11279P	P 19960207 <--
			US 1996-27688P	P 19961008 <--
			JP 1997-528123	A3 19970130 <--
			WO 1997-EP459	W 19970130 <--
			US 1999-117717	A1 19990302 <--

OTHER SOURCE(S): MARPAT 127:220669


IT 16142-51-1P 195054-42-3P 195054-43-4P
 195054-44-5P 195054-45-6P 195054-46-7P
 195054-47-8P 195054-48-9P 195054-49-0P
 195054-50-3P 195054-51-4P 195054-52-5P
 195054-53-6P 195054-54-7P 195054-55-8P
 195054-90-1P 195055-15-3P 195055-18-6P
 195055-21-1P 195055-43-7P 195055-44-8P
 195055-45-9P 195055-46-0P 195055-47-1P
 195055-53-9P 195055-54-0P 195055-55-1P
 195055-56-2P 195055-82-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)


RN 16142-51-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,2,5-trimethyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 195054-42-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-43-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 195054-44-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1,1-dimethylethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-45-6 CAPLUS

CN 1-Propanol, 3-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195054-46-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-47-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-48-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 195054-49-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-50-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1,2-dimethylpropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 195054-51-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1,3-dimethylbutyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 195054-52-5 CAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-4-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195054-53-6 CAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-4-methyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195054-54-7 CAPLUS


CN 1-Butanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-3-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195054-55-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195054-90-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-butyl-3-(2,4-dichlorophenyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 195055-15-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(2-methoxy-1-methylethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 195055-18-6 CAPLUS
 CN 1-Hexanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-21-1 CAPLUS
 CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-43-7 CAPLUS

CN 1-Hexanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-44-8 CAPLUS

CN 1-Pentanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 195055-45-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chlorophenyl)-2,5-dimethyl-N-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)



RN 195055-46-0 CAPLUS


CN 1-Pentanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-4-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195055-47-1 CAPLUS

CN 1-Hexanol, 2-[[3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-53-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-54-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 195055-55-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1,3-dimethylbutyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-56-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N,2,5-trimethyl- (9CI) (CA INDEX NAME)



RN 195055-82-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [R = (un)substituted Ph, pyridyl; R1 = substituted NH₂, (un)substituted alkoxy; R2 = alkyl, alkoxy, alkylthio; R3 = H, alkyl, alkylsulfonyl, alkylsulfoxy, alkylthio] having CRF receptor antagonistic properties, were prepared Thus, I [R = 2,4-Cl₂C₆H₃, R1 = N-propyl-N-cyclopropylmethylamino, R2 = Me, R3 = H, II] was obtained by treating 3-amino-4-(2,4-dichlorophenyl)pyrazole with MeCOCH₂CO₂Et, chlorinating I [R = 2,4-Cl₂C₆H₃, R1 = OH, R2 = Me, R3 = H] and aminating I [R1 = Cl]. II had a K_i for CRF receptor inhibition of <250 nM.

L5 ANSWER 29 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:196727 CAPLUS
DOCUMENT NUMBER: 124:261026
TITLE: Preparation and formulation of pyrazolopyrimidine derivatives as analgesics
INVENTOR(S): Shoji, Yasuo; Inoue, Makoto; Okamura, Takashi; Hashimoto, Kinji; Ohara, Masayuki; Yasuda, Tsuneo
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9535298	A1	19951228	WO 1995-JP1104	19950605 <--
W: AU, CA, CN, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2169719	A1	19951228	CA 1995-2169719	19950605 <--
CA 2169719	C	20020416		
AU 9525765	A	19960115	AU 1995-25765	19950605 <--
AU 680370	B2	19970724		
EP 714898	A1	19960605	EP 1995-920260	19950605 <--
EP 714898	B1	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1131948	A	19960925	CN 1995-190760	19950605 <--
CN 1046730	B	19991124		
JP 08311068	A	19961126	JP 1995-137878	19950605 <--
JP 3163412	B2	20010508		
JP 08310951	A	19961126	JP 1995-137890	19950605 <--
JP 3163413	B2	20010508		
AT 208776	T	20011115	AT 1995-920260	19950605 <--
ES 2164153	T3	20020216	ES 1995-920260	19950605 <--
PT 714898	T	20020429	PT 1995-920260	19950605 <--
US 5707997	A	19980113	US 1996-602824	19960221 <--
PRIORITY APPLN. INFO.:			JP 1994-138635	A 19940621 <--
			JP 1995-53997	A 19950314 <--
			WO 1995-JP1104	W 19950605 <--


OTHER SOURCE(S): MARPAT 124:261026

IT 174859-38-2P 174859-40-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidine derivs. as analgesics)


RN 174859-38-2 CAPLUS

CN Benzamide, N-[5-butyl-2-phenyl-3-[4-(phenylthio)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 174859-40-6 CAPLUS


CN Benzamide, N-(5-butyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



GI



I




II

AB The title compds. I [R1 represents hydrogen, lower alkyl, cycloalkyl,


thienyl, furyl, lower alkenyl or phenyl; R2 represents naphthyl, cycloalkyl, furyl, thienyl, pyridyl, phenoxy or phenyl; R3 represents hydrogen, Ph or lower alkyl; R4 represents hydrogen, lower alkyl, lower alkoxy carbonyl, phenyl-substituted lower alkyl, Ph or halogen; R5 represents hydrogen or lower alkyl; R6 represents hydrogen, lower alkyl, phenyl-substituted lower alkyl or benzoyl; Q represents carbonyl or sulfonyl; A represents a single bond, lower alkylene or lower alkenylene; and n represents 0 or 1] are prepared. The title compound II (preparation given) at 3 mg/Kg orally showed potent analgesic activity in rats.

ACCESSION NUMBER: 1993:213102 CAPLUS
 DOCUMENT NUMBER: 118:213102
 TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives
 antiinflammatory agents
 INVENTOR(S): Inoue, Makoto; Hashimoto, Kinji; Kuwahara, Toshiko;
 Sugimoto, Yukio; Uesako, Takuji; Funato, Toshiaki
 PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9218504	A1	19921029	WO 1991-JP1043	19910806 <--
W: AU, CA, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2107479	A1	19921023	CA 1991-2107479	19910806 <--
CA 2107479	C	19971216		
AU 9182958	A	19921117	AU 1991-82958	19910806 <--
AU 651986	B2	19940811		
EP 591528	A1	19940413	EP 1991-913666	19910806 <--
EP 591528	B1	19981223		
R: AT, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
AT 174917	T	19990115	AT 1991-913666	19910806 <--
ES 2126573	T3	19990401	ES 1991-913666	19910806 <--
JP 05070353	A	19930323	JP 1992-55370	19920313 <--
US 5688949	A	19971118	US 1993-133086	19931007 <--
PRIORITY APPLN. INFO.:			JP 1991-90707	A 19910422 <--
			WO 1991-JP1043	A 19910806 <--
OTHER SOURCE(S):			MARPAT 118:213102	
IT 137739-40-3P 137739-41-4P 137739-43-6P				
137739-44-7P 137739-55-0P 137739-56-1P				
137739-59-4P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of, as antiinflammatory agent)				
RN 137739-40-3 CAPLUS				
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (9CI) (CA INDEX NAME)				




RN 137739-41-4 CAPLUS
 CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 137739-43-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[[2-(methoxycarbonyl)phenyl]amino]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137739-44-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[[4-hydroxy-3-(methoxycarbonyl)phenyl]amino]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137739-55-0 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (9CI) (CA INDEX NAME)



RN 137739-56-1 CAPLUS


CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, monosodium salt (9CI) (CA INDEX NAME)







● Na

RN 137739-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[(3-carboxy-4-hydroxyphenyl)amino]-3-phenyl- (9CI) (CA INDEX NAME)



GI




AB The title compds. [I; R¹-R⁴ = H, CO₂H, Ph, alkoxycarbonyl, alkyl, cycloalkyl, etc.; R¹R² = alkylene; R⁵ = SR⁶, NR⁷R⁸ (wherein R⁶ = pyridyl, Ph or substituted Ph; R⁷, R⁸ = H, Ph or substituted Ph, etc.)] are prepared A suspension of Cl compound II (R = Cl) 3.5, aniline salt III 6.0, and PhNEt₂ 6.0 in MePh was heated at 120° to give 4.7 g IV, which showed IC₅₀ of 3 + 10⁻⁷M against cyclooxygenase. IV showed 65.0% inhibition against cyclooxygenase at 3 + 10⁻⁷M, vs. 12.4% with indomethacin.


L5 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:6580 CAPLUS
DOCUMENT NUMBER: 116:6580
TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives
as drugs
INVENTOR(S): Inoue, Makoto; Hashimoto, Kinji
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 03204877	A	19910906	JP 1990-289769	19901025 <--
JP 2585462	B2	19970226		
PRIORITY APPLN. INFO.:			JP 1989-277566	A1 19891025 <--
OTHER SOURCE(S):	MARPAT 116:6580			
IT	137739-40-3P 137739-41-4P 137739-43-6P 137739-44-7P 137739-55-0P 137739-56-1P 137739-59-4P			
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as drug)			
RN	137739-40-3 CAPLUS			
CN	Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-methyl-3-phenylpyrazolo[1,5- a]pyrimidin-7-yl)amino]- (9CI) (CA INDEX NAME)			




RN 137739-41-4 CAPLUS
CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-,
methyl ester (9CI) (CA INDEX NAME)



RN 137739-43-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[[2-(methoxycarbonyl)phenyl]amino]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137739-44-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[[4-hydroxy-3-(methoxycarbonyl)phenyl]amino]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137739-55-0 CAPLUS
 CN Benzoic acid, 2-hydroxy-5-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-

yl)amino]- (9CI) (CA INDEX NAME)



RN 137739-56-1 CAPLUS


CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 137739-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[(3-carboxy-4-hydroxyphenyl)amino]-3-phenyl- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1-R4 = H, CO₂H, alkoxy carbonyl, Ph, (HO-, HO₂C-, or alkoxy carbonyl-substituted)alkyl, cycloalkyl; or R1R2 = alkylene; R5 = SR6, NR7R8; R6 = pyridyl, (1-3 HO- or alkyl-substituted) Ph; R7, R8 = H, (1-3 HO-, alkyl-, alkoxy carbonyl-, or HO₂C-substituted) Ph; or NR7R8 = 1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, (un)substituted 1-piperazinyl], useful as antiinflammatories, antirheumatics, antiasthmatics, allergy inhibitors, antipyretics, and analgesics and for improvement of ischemia (no data), are prepared Thus, a suspension of 1.0 g 7-chloropyrazolo[1,5-pyrimidine, 1.8 g 3,5-di-tert-butyl-4-hydroxyaniline-HCl, and 2.3 mL PhNEt₂ in PhMe was heated 30 min at 120° to give 890 mg I (R1-R4 = H, R5 = 3,5-di-tert-butyl-4-hydroxyphenylamino). A total of 48 I were prepared

L5 ANSWER 32 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:47662 CAPLUS

DOCUMENT NUMBER: 104:47662

TITLE: Purine analog inhibitors of xanthine oxidase -
structure activity relationships and proposed binding
of the molybdenum cofactor

AUTHOR(S): Robins, Roland K.; Revankar, Ganapathi R.; O'Brien,
Darrell E.; Springer, Robert H.; Novinson, Thomas;
Albert, Anthony; Senga, Keitaro; Miller, Jon P.;
Streeter, David G.

CORPORATE SOURCE: Cancer Res. Cent., Brigham Young Univ., Provo, UT,
84602, USA

SOURCE: Journal of Heterocyclic Chemistry (1985),
22(3), 601-34
CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 104:47662

IT 99898-59-6P 99898-60-9P 99898-61-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of and xanthine oxidase inhibition by)


RN 99898-59-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(3-methylphenyl)- (9CI) (CA
INDEX NAME)




RN 99898-60-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-dimethyl-3-(3-methylphenyl)- (9CI)
(CA INDEX NAME)




RN 99898-61-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-methylphenyl)-N-propyl- (9CI) (CA
INDEX NAME)



AB An updated study of structure-activity relations and binding to xanthine oxidase of hypoxanthine analogs is presented. In view of the recent elucidation of the pterin cofactor and the proposed binding of this factor to the Mo ion in xanthine oxidase, a detailed mechanism of xanthine oxidase oxidation of hypoxanthine and xanthine is proposed. Three types of substrate binding are viewed for xanthine oxidase: the binding of xanthine to xanthine oxidase is termed Type I binding, the binding of hypoxanthine is termed Type II binding, and the specific binding of alloxanthine is called Type III binding. These 3 types of substrate binding were determined for the most potent known inhibitors of xanthine oxidase, and these inhibitors were classified as to the type of inhibitor binding most likely to be associated with specific enzyme inhibition. The structural requirements for each type of binding can be clearly seen to correlate with the inhibitory activity observed. The chemical syntheses of the new 3-phenyl- and 3-substituted phenylpyrazolo[1,5-a]pyrimidines with various substituents are reported. The syntheses of various 8-phenyl-2-substituted pyrazolo[1,5-a]-s-triazines, certain s-triazolo[1,5-a]-s-triazines and s-triazolo[1,5-a]pyrimidine derivs. prepared in connection with the present study are also described.


L5 ANSWER 33 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1971:405833 CAPLUS
 DOCUMENT NUMBER: 75:5833
 TITLE: Acyl enamines. 18. Reaction of
 phenylcyanoacetaldehyde with hydrazine
 AUTHOR(S): Eiden, Fritz; Evers, G.
 CORPORATE SOURCE: Pharm. Inst., Freie Univ. Berlin, Berlin, Fed. Rep.
 Ger.
 SOURCE: Archiv der Pharmazie und Berichte der Deutschen
 Pharmazeutischen Gesellschaft (1971),
 304(2), 121-5
 CODEN: APBDAJ; ISSN: 0376-0367
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 IT 32016-26-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 32016-26-5 CAPLUS
 CN Acetamide, N-(3,6-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI) (CA INDEX
 NAME)



AB Reaction of $\text{PhCH}(\text{CN})\text{CHO}$ with $\text{H}_2\text{NNH}_2 \cdot \text{H}_2\text{O}$ in C_6H_6 in the presence of
 $p\text{-MeC}_6\text{H}_4\text{SO}_3\text{H}$ gave 73% I (and II ($\text{R} = \text{R}_1 = \text{H}$) (III) by-product) but no
 $\text{PhCH}(\text{CN})\text{CH}:\text{NN}:\text{CHCH}(\text{CN})\text{Ph}$ (described by E. L. Anderson, et al. (1964)).
 Heating III in Ac_2O and concentrated H_2SO_4 gave 63% II ($\text{R} = \text{R}_1 = \text{Ac}$) and some
 II ($\text{R} = \text{H}$, $\text{R}_1 = \text{Ac}$).

ACCESSION NUMBER: 1971:22872 CAPLUS
 DOCUMENT NUMBER: 74:22872
 TITLE: 7-Aminoalkylaminopyrazolo[1,5-a]pyrimidine derivatives
 INVENTOR(S): Takamizawa, Akira
 PATENT ASSIGNEE(S): Shionogi and Co., Ltd.
 SOURCE: Jpn. Tokkyo Koho, 3 pp.
 CODEN: JAXXAD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 45030335	B4	19701001	JP 1966-81943	19661214 <--
IT	30156-81-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	30156-81-1 CAPLUS				
CN	1-Piperidineacetamide, N-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI) (CA INDEX NAME)				



GI For diagram(s), see printed CA Issue.
 AB I is treated with an amine and the resulting II reduced to manufacture III, useful as an antipyretic, analgesic, and antiinflammatory drug. In an example, I in CHCl₃ is refluxed 5 hr with piperidine to give II (A = piperidino), m. 195-6°. Similarly prepared are the following II (A given): morpholino; NMe₂. III (A = piperidino) in THF is dropped into a suspension of LiAlH₄ in THF and the mixture refluxed 4 hr to give III (A = piperidino). Similarly prepared are the following III (A given): morpholino; NMe₂.

L5 ANSWER 35 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1968:114635 CAPLUS
 DOCUMENT NUMBER: 68:114635
 TITLE: 7-Haloacylamino-pyrazolo[1,5-a]pyrimidines
 INVENTOR(S): Takamizawa, Akira
 PATENT ASSIGNEE(S): Shionogi and Co., Ltd.
 SOURCE: Jpn. Tokkyo Koho, 2 pp.
 CODEN: JAXXAD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO. -----	KIND ----	DATE -----	APPLICATION NO. -----	DATE -----
	JP 42016314	B4	19670904	JP	19640629 <--
IT	17560-60-0P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	17560-60-0 CAPLUS				
CN	Acetamide, 2-chloro-N-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI) (CA INDEX NAME)				




AB 2,3-Dimethyl-7-aminopyrazolo[1,5-a]pyrimidine (5.7 g.) in 40 ml. Me₂NCHO is treated with 4 g. ClCH₂COCl with ice-cooling and the whole heated to give 1.94 g. 2,3-dimethyl-7-chloroacetamidopyrazolo[1,5-a]pyrimidine, m. 175° (MeOH). Similarly prepared are the following R-substituted-7-chloroacetamidopyrazolo[1,5-a]pyrimidines (R and m.p. given): 2,3,6-trimethyl, 139-41°; 2,5-dimethyl-3-phenyl, 158-9°. The products are then subjected to aminolysis to give antipyretic, analgesic, and antiphlogistic drugs.


L5 ANSWER 36 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1967:508663 CAPLUS
DOCUMENT NUMBER: 67:108663
TITLE: 7-Methylaminopyrazolo[1,5-a]pyrimidine derivatives
INVENTOR(S): Takamizawa, Akira; Hamashima, Yoshio
PATENT ASSIGNEE(S): Shionogi and Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	JP 42011753	B4	19670704	JP	19640120 <--
IT	16142-50-0P 16142-51-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	16142-50-0 CAPLUS				
CN	Formamide, N-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI) (CA INDEX NAME)				



RN 16142-51-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,2,5-trimethyl-3-phenyl- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.
AB cf. preceding abstract Manufacture of Ia (I where X is NHMe), useful as sedative and antiphlogistic agents, starting from Ib (I where X is NH₂) via Ic (I where X is NHCHO) is described. In an example, 5 ml. acid anhydride of a mixture of HCO₂H and Ac₂O is added to 1 g. ice-cooled Ib (R₁ = R₂ = Me, R₃ = R₄ = H), the whole let stand for 1.5 days, concentrated in vacuo, and the residue recrystd. (Me₂CO) to give 0.95 g. Ic (R₁ = R₂ = Me, R₃ = R₄ = H), pale green, m. 189°. Similarly prepared are the following Ic (R₁, R₂, R₃, R₄, and m.p. given): Me, Me, H, Me (pale green), 183°; Me, Ph, Me, H (pale yellow), 184° (decomposition); PhCH₂, Me, Me, H, 131-2°. Ic (R₁ = R₂ = Me, R₃ = R₄ = H) (1 g.) in 30 ml.

tetrahydrofuran is added to icecooled mixture of 0.7 g. LiAlH_4 and 50 ml. tetrahydrofuran, the mixture heated at 70° for 5 hrs., NaOH solution added, the tetrahydrofuran layer separated and concentrated, and the residue extracted

with CHCl_3 to give 0.83 g. Ia ($\text{R}_1 = \text{R}_2 = \text{Me}$, $\text{R}_3 = \text{R}_4 = \text{H}$), m. 146° (Et_2O). Similarly prepared are the following Ia (R_1 , R_2 , R_3 , R_4 , and m.p. given): Me, Me, H, Me, 157° ; Me, Ph, Me, H, $190-1^\circ$; PhCH_2 , Me, Me, H, (oil) (picrate m. $207-8^\circ$).

L5 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1967:410663 CAPLUS

DOCUMENT NUMBER: 67:10663

TITLE: The electrocardiographic picture in the acute experimental poisoning from organic phosphorus compounds

AUTHOR(S): Orlando, E.; Raffi, G. B.; Zini, C.

CORPORATE SOURCE: Ist. Med., Univ. Bologna, Bologna, Italy

SOURCE: Lavoro Umano (1966), 18(11), 493-501

CODEN: LAUMAL; ISSN: 0023-9127

DOCUMENT TYPE: Journal


LANGUAGE: Italian

IT 16142-50-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16142-50-0 CAPLUS

CN Formamide, N-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI)
(CA INDEX NAME)




AB A study of the electrocardiographic changes effected by parathion, administered i.v. into rabbits at an acute poisoning dose of 12.5 mg./kg. body weight, suggested that electrolyte imbalances effected by organic P compds. play a role in the genesis of these electrocardiographic changes.


ACCESSION NUMBER: 1966:75800 CAPLUS
 DOCUMENT NUMBER: 64:75800
 ORIGINAL REFERENCE NO.: 64:14196h,14197a-b
 TITLE: 7-Substituted carbonylaminopyrazolo[1,5-
 α]pyrimidine derivatives
 INVENTOR(S): Takamizawa, Akira; Hamashima, Yoshio
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd.
 SOURCE: 3 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 41001864	B4	19660209	JP	19630907 <--

PRIORITY APPLN. INFO.: JP 19630907 <--
 IT 5299-74-1P, Urea, 3-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]-
 pyrimidin-7-yl)-1,1-dimethyl- 5299-76-3P, Pyrazolo[1,5-
 α]pyrimidine-7-carbamic acid, 2,5-dimethyl-3-phenylthio-, S-ethyl ester
 5313-71-3P, Pyrazolo[1,5-a]pyrimidine-7-carbamic acid,
 2,5-dimethyl-3-phenyl-, ethyl ester
 RL: PREP (Preparation)
 (preparation of)
 RN 5299-74-1 CAPLUS
 CN Urea, 3-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-1,1-dimethyl-
 (7CI, 8CI) (CA INDEX NAME)




RN 5299-76-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-7-carbamic acid, 2,5-dimethyl-3-phenylthio-,
 S-ethyl ester (7CI, 8CI) (CA INDEX NAME)



RN 5313-71-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-7-carbamic acid, 2,5-dimethyl-3-phenyl-, ethyl

ester (7CI, 8CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB Manufacture of I, useful as tranquilizer and antiinflammatory agents, is described. Thus, a mixture of 1 g. 2,3-dimethyl-7-aminopyrazolo[1,5-a]pyrimidine and 0.67 g. ClCO₂Et in 20 ml. Me₂CO is heated at 100° for 4 hrs. in a sealed tube, cooled, filtered, the filtrate extracted with CHCl₃, and the extract concentrated to give 0.83 g. I (R₁ = R₂ = Me, R₃ = H,

R₄ = OEt), columns, m. 113° (Et₂O); hydrochloride m. 188°. Similarly prepared are the following I (R₁, R₂, R₃, R₄, and m.p. given): Me, Me, H, NMe₂, 163° (hydrochloride m. 210-13°); Me, Me, H, morpholino, -- (hydrochloride m. 208°); Me, Me, H, piperidino, 136°; Me, Ph, Me, OEt, 148-9°; Me, Ph, Me, NMe₂, 148-50°; Bz, Me, Me, OEt, 92°; Me, Ph, Me, SEt, 105°; Bz, Me, Me, SEt, 98-9°; Bz, Me, Me, NMe₂, 137-8°; Bz, Me, Me, piperidino, 118-19°.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	211.46	383.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-29.64	-29.64

STN INTERNATIONAL LOGOFF AT 09:42:32 ON 05 SEP 2007